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ABSTRACT

SYNTHESIS OF NOVEL 5-SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINE
ANTIFOLATES AS SELECTIVE AND POTENT ANTI-TUMOR AGENTS

By
Mohammad Anwarul Karim
May 2018

Dissertation supervised by Professor Aleem Gangjee
In last few decades many folate analogs have been discovered and several
compounds are successfully being used as anticancer agents. Methotrexate (MTX),
pemetrexed (PMX), raltitrexed (RTX): are a few examples of classical antifolates that are
currently in clinical use. Although these compounds are widely used, all of them show dose
limiting toxicity due to their non-specific transport into normal cells as well as malignant
cells. Currently, clinically used classical antifolates suffer from this disadvantage because
there is no way to selectively transport them into malignant cells. Currently available
antifolates are transported via reduced folate career (RFC) as well as Folate receptors (FRs)
and/or Proton coupled folate transporter (PCFT). Because RFC is ubiquitous in the human
body, the dose limiting toxicity is unavoidable for an antifolate if it is a substrate for RFC.
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To circumvent this challenge with antifolate chemotherapy, it is necessary to develop
agents which are selective for the cancerous tissues. Exploiting the site specificity of FRs
and/or the acidic pH specificity of PCFT, the goal of developing targeted antifolate agents
could be achieved. This approach of selective transport into tumor cells via FRs and/or
PCFT and over RFC targets inhibition of GARFTase dependent salvage pathway for purine
biosynthesis inside the tumor. Based on this premise, five 5-substituted pyrrolo[2,3d]pyrimidines have been designed, synthesized and characterized. Among them four are
novel compounds and one is a previously reported compound. The previously reported
compound has never been tested for FR/PCFT-GARFTase selectivity before, and therefore
was of interest and was synthesized.

Figure (abstract). 5-substituted pyrrolo[2,3-d]pyrimidine with variation in the linker
length and side chain aromatic group.
To investigate the role of side chain aromatic group in the folate analogs, phenyl,
fluorophenyl and furan groups have been placed in the linker region. The compounds
comprise of different aliphatic linker chain length from 2C to 5C. To test selectivity, FR
and PCFT transport have been studied and GARFTase inhibitory assay will be conducted.

v

DEDICATION

Dedicated To My Family.

vi

ACKNOWLEDGEMENT

I would like to thank all of those who have contributed to this work. In particular I
am most grateful to Professor Dr. Aleem Gangjee, my supervisor, for his help and support
which made this thesis possible. I am indebted to him not just for his scientific contribution
but also for his motivating words, financial support and his mentoring. I would like to thank
the members of my dissertation committee: Drs. Marc W. Harrold, Kevin Tidgewell and
Aleem Gangjee for their scientific and academic support. I wish to thank Dr. Larry H.
Matherly at Barbara Ann Karmanos Cancer Institute, Wayne State University School of
Medicine for evaluating all the compounds for enzyme inhibitory activity and antitumor
activity. I wish to express my sincere appreciation to Nancy Hosni in the office of pharmacy
school for her help and assistance. My thanks goes to all my colleagues in the Graduate
School of Pharmaceutical Sciences, especially to my three lab-mates, for their help and
advice which made my stay at Duquesne University a most pleasant experience. I would
like to thank the Graduate School of Pharmaceutical Sciences for the financial support
provided to me. Finally, I would like to pay tribute to the constant support of my family
and my friends. I would specially thank my loving wife Mahmuda for her amazing support
during the demanding process of research and thesis writing.

vii

TABLE OF CONTENTS
Page
Abstract .............................................................................................................................. iv
Dedication .......................................................................................................................... vi
Acknowledgement ............................................................................................................ vii
List of Tables ..................................................................................................................... ix
List of Figures ......................................................................................................................x
List of Schemes .................................................................................................................. xi
List of Abbreviations ....................................................................................................... xiii
I. Biochemical Review .........................................................................................................1
II. Chemical Review ..........................................................................................................25
III. Statement of the Problem .............................................................................................35
IV. Chemical Discussion ...................................................................................................45
V. Summary .......................................................................................................................56
VI. Experimental ................................................................................................................59
Bibliography ......................................................................................................................82
Appendix ...........................................................................................................................95

viii

LIST OF TABLES
Page
Table 1. GARFTase inhibitors: 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8dihydro-pyrimido[5,4-b][1,4]thiazines ……………………………………………….....21
Table 2. GARFTase inhibitors: FRα- and PCFT-substrates……………….………….....23
Table 3. IC50s (in nM) for 5- substituted pyrrrolo[2,3-d]pyrimicline antifolates 6, 7, 8, 10
and classical antifolates in RFC-, PCFT-, and FR-expressing cell lines …..……………56

ix

LIST OF FIGURES
Page
Figure (abstract). Pyrrolo[2,3-d]pyrimidine with variation at bridge, side chain and
terminal L-gluatmic acid…………………………….………………………………….....v
Figure 1. Folic acid structure.………...…………………………………………………...1
Figure 2. Folate’s role in nucleic acid and amino acid synthesis ………………………...2
Figure 3. DNA/RNA via de novo purine bio-synthesis…………………………………...5
Figure 4. Classical antifolates and their targets…………........…………………………...6
Figure 5. Non-classical antifolates and their targets….…………………………………...6
Figure 6. Catalytic mechanism of GARFTase…………………………………………...18
Figure 7. Representative 5-substituted and 6-substituted pyrrolo[2,3-d]pyrimidines with
only GARFTase inhibition or GARFTase/AICARFTase dual inhibition…..…………...24
Figure 8. The structures of classical 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidine antifolates 4 and 5 ………………………………………………………......35
Figure 9. The structures of classical 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidine antifolates 6-10…………………………………………….………………...37
Figure 10. Molecular modeling studies of compounds 5 and 8 with FRα……………….39
Figure 11. Ligand interaction map of 5 and 8 in human FRα …...………………………40
Figure 12. Molecular modeling studies of compounds 5 and 8 with GARFTase….……41
Figure 13. Ligand interaction map of 5 and 8 in GARFTase. …...…………………..42-43

x

LIST OF SCHEMES
Page
Scheme 1. Synthesis of pyrrolo[2,3-d]pyrimidines 28.………..………………………...25
Scheme 2. Synthesis of pyrrolo[2,3-d]pyrimidines 31 and 34……………………..…….26
Scheme 3. Synthesis of 8-trifluoromethyldeazaguanine……………………………....…26
Scheme 4. 5-substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidines…………..….26
Scheme 5. Synthesis of pyrrolo[2,3-d]pyrimidines 48 and 50 and furo[2,3-d]pyrimidines
47………………………………………………………………..………………….…….27
Scheme 6. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57……………….…….28
Scheme 7. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57 and 60………..……29
Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidine 62 from 6-amino-5-pyrimidylacetaldehydes 61………………...………………………………………………………………..29
Scheme 9. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization...........30
Scheme 10. Synthesis of pyrrolo[2,3-d]pyrimidine 78……….………………………….30
Scheme 11. Synthesis of pyrrolo[2,3-d]pyrimidines 87.…………………………....…...31
Scheme 12. Synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 92.….....31
Scheme 13. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 94.....….…..32
Scheme 14. Synthesis of N7-substituted analogs of PMX………………………….....…33
Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidine 107 and PMX………….………..…34
Scheme 16. Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 110…...……….34
Scheme 18. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine
6…………………………………………………………………………….…...……….45

xi

Scheme 19. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine
7………………………………………………………………………………………….47
Scheme 20. Alternative scheme for synthesis of 2-amino-4-oxo-5-substitutedpyrrolo[2,3-d]pyrimidine 7……………………………………………………...……….48
Scheme 21. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine
8…………………………………………………………………………….…...……….51
Scheme 22. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine
9…………………………………………………………………………….…...……….52
Scheme 23. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine
10…………………………………………………………………………..…...……….54

xii

LIST OF ABBREVIATIONS

AICAR

Aminoimidazole-4-carboxamide ribosyl-5-phosphate

AICARFTase

Aminoimidazole-4-carboxamide ribosyl-5-phosphate formyl
transferase

AIDS

Acquired Immunodeficiency Syndrome

ALL

Acute Lymphoblastic Leukemia

AMT

Aminopterin

ARDS

Acute Respiratory Distress Syndrome

Arg

Arginine

ATP

Adenosine-5’-triphosphate

CAM

Chorioallantoic membrane

CNS

Central nervous system

DHFR

Dihydrofolate reductase

DMAI

Disseminated Mycobacterium avium intracellulare

DMAP

4-Dimethylamino pyridine

DMF

N,N-dimethyl formamide

DMSO

Dimethyl sulfoxide

DNA

Deoxyribonucleic acid

dATP

2’-Deoxyadenosine-5’-triphosphate

dGTP

2’-Deoxyguanosine 5’-triphosphate

dTDP

2’-Deoxythymidine 5’-diphosphate

xiii

dTMP

2’-Deoxythymidine-5’-monophosphate

dTTP

2’-Deoxythymidine-5’-triphosphate

dUMP

2’-Deoxyuridine-5’-monophosphate

dUTP

2’-Deoxyuridine-5’-triphosphate

E. coli

Escherichia coli

FA

Folic Acid

FH2

7,8-Dihydrofolate

FH4

5,6,7,8-Tetrahydrofolate

FPGH

Folylpolyglutamate Hydrolase

FPGS

Folyl Poly--glutamate Synthetase

FR

Folate Receptor

FdUMP

5-Fluoro-2’-deoxyuridine-5’-monophosphate

GAR

Glycinamide Ribosyl-5-phosphate

GARFTase

Glycinamide Ribonucleotide Formyl Transferase

GDP

Guanosine Diphosphate

GTP

Guanosine triphosphate

IMP

Inositol Monophosphate

MRP

Multidrug Resistance Protein

MTHFR

Methylene Tetrahydrofolate Reductase

MTX

Methotrexate

NADPH

Nicotinamide Adenine Dinucleotide Phosphate

NCI

National Cancer Institute

xiv

NMR

Nuclear Magnetic Resonance

NRTI

Nucleoside reverse transcriptase inhibitors

PABA

Para-amino Benzoic Acid

PDB

Protein Data Bank

PDDF

N10-propargyl-5,8-dideazafolate

Pgp

P-glycoprotein

PTX

Piritrexim

Rh

Recombinant human

rl

Rat liver

RNA

Ribonucleic Acid

RFC

Reduced Folate Carriers

SHMT

Serine Hydroxymethyl Transferase

TLC

Thin Layer Chromatography

TMP

Trimethoprim

TMQ

Trimetrexate

Trp

Tryptophan

TS

Thymidylate Synthase

xv

I. BIOCHEMICAL REVIEW

Folic acid (FA) is a water soluble vitamin which was first reported nearly eight decades
ago. The compound was first isolated by Mitchell et al.1 in 1941. Tetrahydrofolate (THF) is a
reduced derivative of folic acid. There are three structural segments in folic acid: a scaffold, which
is a hetero-bicyclic pteridine ring; a linker, which is p-amino benzoic acid (PABA); and a terminal
portion, glutamic acid (Figure 1). FA also has an alternate name of pteroylglutamic acid. In nature
FA is not found in its original chemical form, rather several derivatives are found. As such, the
natural forms of folic acid derivatives are represented by the term folates and the oxidized synthetic
form that is used in dietary supplements is represented by the term folic acid. There are several
oxidized and reduced states of folates (oxidized, 7,8-H2, and 5,6,7,8-H4). On N5 or N10 or on both
nitrogen atoms of the molecule, one carbon units can be attached. There could also be additional
glutamate units attached via γ-peptide bonds to yield folate polyglutamates.

Figure 1. Folic acid structure1
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1. Role of folate in biochemical processes

Figure 2. Folate’s role in nucleic acid and amino acid synthesis1-2
Folic acid is necessary for DNA synthesis and the metabolic cycle of folic acid plays an
important role in mammal biochemistry. In the folic acid metabolism cycle, the one carbon transfer
occurs to amino acids, nucleotides and biomolecules. Intestinal absorption by the proton coupled
folate transporter (PCFT) is the major mechanism of folic acid absorption. Tetrahydrofolic acid
(THF) is generated from folic acid. For this generation process, a NADPH (nicotinamide adenine
dinucleotide phosphate) specific enzyme, dihydrofolate reductase (DHFR), reduces folic acid
2

either partially or fully to yield 7,8-dihydrofolate (DHF) or 5,6,7,8-tetrahydrofolate (THF)
respectively. Further oxidative enzymatic modification makes THF a one carbon donor. The
residual dihydrofolate can be converted to tetrahydrofolate. Any compound that can act as an
inhibitor in any of the steps in folate metabolism is called an antifolate. These antimetabolites have
chemotherapeutic application potential.
In intracellular homocysteine remethylation process, 5-MethylTHF acts as a methyl donor.
Serine hydroxymethyltransferase (SHMT), a vitamin B6-dependent enzyme, converts THF into
5,10-methyleneTHF. Two isoforms of SHMT have been identified and they utilize serine as a onecarbon donor. A trifunctional enzyme, methylenetetrahydrofolate dehydrogenase (MTHFD), is
responsible for converting THF into 5,10-methyleneTHF, via N10-formylTHF and 5,10methenylTHF. N10-formylTHF plays a role in the purine biosynthesis pathway as a one carbon
donor and 5,10-methylene THF plays a role in converting dUMP into dTMP.2 dUMP to dTMP
conversion is catalyzed by the enzyme thymidylate synthase (TS). TS utilizes 5,10-methyleneTHF
both as a methyl source and as a reductant. 5,10-MethyleneTHF is converted to dihydrofolate
(DHF) by simultaneous transfer of a methylene group and the 6-hydrogen atom as hydride. As
mentioned previously, this DHF could be converted back to THF via the action of DHFR.
In the de novo purine biosynthesis pathway there are two folate-related enzymes, βglycinamide-ribonucleotide transformylase (GARFTase) and aminoimidazolecarboxamide
ribosyl-5-phosphate formyl transferase (AICARFTase), that transfer a one carbon unit. These two
enzymes utilizes CHO-THF as the one carbon donor. (Figure 3).3 These transferred one-carbon
units are the C-8 and C-2 of synthesized purines. The first enzyme, GARFTase, is part of a
trifunctional protein which is active in the second, third and fifth step of purine biosynthesis
pathway. The third step is GARFTase specific (Figure 3) where this enzyme utilizes N10-formyl3

THF to convert glycinamide ribosyl-5-phosphate (GAR) to formyl-glycinamide ribosyl-5phosphate (fGAR). fGAR is converted to amino-imidazolecarboxamide ribosyl-5-phosphate
(AICAR) in later steps. Then another one-carbon transfer from N10-CHO-THF occurs when aminoimidazolecarboxamide

ribosyl-5-phosphate

(AICAR)

is

converted

to

formyl-amino-

imidazolecarboxamide ribosyl-5-phosphate (fAICAR) by amino-imidazolecarboxamide ribosyl5-phosphate formyl transferase (AICARFTase). Futher conversion of fAICAR yields important
intermediate inosine-5’-monophosphate (IMP). IMP is significant because it is a precursor of the
following intermediates: adenosine-5’-triphosphate (ATP) and guanosine-5’-triphosphate (GTP)
in the ribonucleic acid (RNA) biosynthesis pathway; 2’-deoxyadenosine-5’-triphosphate (dATP)
and 2’-deoxyguanosine-5’-triphosphate (dGTP) in the DNA biosynthesis pathway.4
Though folates are instrumental in several biochemical reactions, their physiological
availability is limited by their chemical nature. Folates cannot be passively diffused across
biological membrane because they are anionic. Because of that, mammals transport folates across
membranes with the help of several transporter molecules. These complex transport molecules
translocate folates as monoglutamates. Inside the cell, the enzyme folylpolyglutamate synthetase
(FPGS) can metabolize folates to add up to eight molecules of L-glutamic acid residues in the γcarboxylic acid portion of each previous glutamate to from folylpoly-γ-glutamate. This process,
known as polyglutamylation, results in, (i) metabolic trapping of folates inside the cell; (ii) binding
of folate dependent enzymes and polyglutamylatedTHF at low concentration of the substrate; and
(iii) greater mitochondrial retention of folates. The polygulamylated folates can be reverted back
to monoglutamylated form via the action of the enzyme γ-glutamyl hydrolase (GGH) which is
present in the lysosomes.5 This GGH enzyme, which is less studied than FPGS, has endo- or
exopeptidase activity depending on the species type. P-glycoprotein (Pgp) and other Multidrug
4

resistance proteins (MRP) have the capability to extrude out monoglutamated folates out of the
cell via ATP dependent pathways.6

Figure 3. DNA/RNA via de novo purine bio-synthesis.7-8
Antifolates are classified into two groups based on the presence or absence of glutamate in
the side chain. These categories are: classical and non-classical antifolates. Because the transport
and polyglutamylation depends on presence of terminal glutamate, these two classes of antifolates
have different membrane transport and polyglutamylation characteristics.5 The first type, classical
antifolates, contain a L-glutamic acid at the side chain. Some examples are: methotrexate (MTX),
aminopterin, pemetrexed (PMX, LY231514, Alimta), raltitrexed (RTX, ZD1694, Tomudex) and
lometrexol (LMTX) (Figure 4). Due to their structural similarity to folates and folate-metabolites,
these molecules are transported into the cell via the folate transporters (i.e. RFC, FR and/or PCFT).
On the other hand, the second type of antifolates lack the terminal L-glutamic acid moiety and thus
are not transported via regular folate transporters. Instead, they are transported via passive or

5

facilitated diffusion.5-6 Some examples of non-classical antifolates are: pyrimethamine,
trimethoprim (TMP) and piritrexim (PTX) (Figure 5).

Figure 4. Classical antifolates and their targets.7

Figure 5. Non-classical antifolates and their targets.7
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2. Folate transport
In mammals there is complete absence of enzymatic mechanism to synthesize folates de
novo. Also, due to their anionic nature, folates cannot be absorbed by passive diffusion. These
reasons makes it necessary to have some kind of mechanism that will facilitate active transport of
folates inside the cell. The mammals indeed have developed molecular mechanisms for folate
transport and three mechanisms have been discovered. These three mechanisms described in the
literature are: the reduced folate carrier (RFC), the folate receptors (FRs) and the proton-coupled
folate transporter (PCFT).9-11 Among these three, reduced folate carrier (RFC) is the dominant
transporter in normal physiological pH. Folate receptors (FRs) are also active at physiological pH,
but their presence is site specific. The two FR types, α and β are proteins attached to cell membrane
via glycosylphosphatidylinositol (GPI) anchors.12 The third type of folate transporter, the protoncoupled folate transporter (PCFT), demonstrates pH dependent activation and is optimally
functional at acidic pH.13-14
2.1. The Reduced Folate Carrier (RFC)
Studies have identified RFC to be the major folate transporter in mammals. Since this
transporter is expressed in almost all major tissues in mammals, it is also the major transporter of
many antifolate molecules. Chemotherapeutic agents, such as, methotrexate, pemetrexed, and
raltitrexed are transported by RFC and their therapeutic, as well as, toxic activity is associated with
the expression of RFC in malignant and normal tissues.15-16
2.1.1. RFC structure
Human RFC is a 591 amino acid long protein which is a member of major facilitator
superfamily (MFS) of transporters. Around 40 years ago, in murine leukemia cells, RFC was first
7

observed and later studies revealed that the rodent RFC is 64-66 percent homologous to the human
RFC.17 The N- and C-termini of RFC is cytoplasmically oriented and the protein comprises of 12
transmembrane domains (TMDs). The loop connecting TMD1 and TMD2 contains a Nglycosylated Asn58. The large loop between TMD6 and TMD7, which is not conserved among
species, can be replaced by non-homologous portions from SLC19A3 carrier.18 In hRFC null cells,
co-expressed TMD1-TMD6 and TMD7-TMD12 domains can restore RFC activity by migrating
to the plasma membrane.
2.1.2. RFC distribution
With its ubiquitous expression and activities at physiological pH, hRFC is the dominant
folate transport system in human cells. hRFC has been identified in liver and placenta in high level
and also found in lung, kidney, intestine, bone marrow, intestine, brain and some segments of
CNS. Other sites where RFC has been detected are: renal tubule epithelium (basolateral
membrane), colon and small intestine (apical brush border), hepatocyte membrane, cell lining of
the spinal canal (apical membrane) and choroid plexus (apical membrane). The importance of RFC
in development has been demonstrated by the finding that targeted homologous recombination to
inactivate both RFC alleles is embryonic lethal in mice.18
2.1.3. RFC transport mechanism
Organic phosphate anions are counter transported against anionic reduced folates by RFC
but inorganic anions inhibit its activity.18 Thus RFC is an anionic antiporter and its physiological
substrate, 5-methylTHF, is the major circulating form of folate.18 It has been reported that RFC’s
affinity for folic acid (Ki ~200 μM) is much lower than its affinity for reduced folates (Ki ~1-5
μM). The Ki for reduced folate is 50 to 100 times lower than folic acid. Physiological pH of 7.4
8

provides the optimum microenvironment for RFC and significant decrease in activity is observed
when the pH goes lower than 7. RFC has to generate substantial electrochemical potential
difference across the cell membrane to transport folates with two negative charges to overcome
the challenge of membrane potential.18 RFC transport is neither linked to ATP hydrolysis nor Na+
or H+ dependent anion transport. Rather, organic phosphate mediated transmembrane anion
gradient facilitates its transport activity.19-20 In contrast to their lower concentration in the
extracellular environment, organic phosphate ions are abundant inside the cell due to their
formation via ATP-dependent reactions. This gradient of organic phosphates across the cell
membrane provides the potential for RFC to actively transport folates in an uphill direction.19-20
2.1.4. RFC in chemotherapy
For transportation purpose, antifolate agents (e.g. MTX, RTX and PMX) mimicking folates
are treated by RFC in the same manner. Thus RFC actively transports classical antifolates in the
same way it actively transports folates.21 To keep an optimum intracellular level of antifolates and
to trap polyglutamylated folate derivatives inside the cell, sustained transport of these chemical
agents is critical. Since, plasma concentration of antifolates (e.g. methotrexate, MTX) decrease
with time, intracellular trapping of mono-glutamate as polyglutamylated antifolates ensures that
target enzymes, like thymidylate synthase and dihydrofolate reductase, are inhibited. Malignant
cells developed resistance exploiting this transport requirement and just six years after it provided
the first metastatic cancer cure, MTX was identified to be resistant in L5178 murine leukemia
cells. Later studies showed that several other classical antifolates have been rendered ineffective
due to this transport impairment resistance mechanism developed by cancer cells.22 To circumvent
this resistance mechanism, drug concentration of antifolates outside the cell could be increased to
gain some success. Higher concentration of extracellular level of drug forces uptake via alternative
9

mechanisms like passive diffusion, which in-turn results in inhibition of folate metabolizing
enzymes. The problem with this approach is that increased level of drug will increase intracellular
concentration both in malignant and non-malignant cell; thus causing toxicity.
2.2. The folate receptors (FRs)
Another type of folate transporter protein is the folate receptor which has three subtypes.
2.2.1. FRs: structure
The three types of folate receptors are: FRα, FRβ and FRγ and their length varies from 229
to 236 amino acids. These proteins share 68 to 79 percent amino acid sequence which makes them
highly homologous. Three FRα and FRβ encoding genes have been identified at chromosome
11q13.3-q13.5 and an FRγ encoding gene, has been identified at chromosome 11q14.23-24 FRα and
FRγ contains two and FRβ contains three N-glycosylation sites in their structure. Unlike RFC,
hFRα and hFRβ are plasma membrane anchored proteins attached through a glycosylphosphatidylinositol (GPI) portion and FRγ is a secreted protein due to the lack of that portion.
In 2013 Karsten Melcher and coworkers25 reported the crystal structure of FRα with folic
acid at 2.8 Å resolution in which they identified that eight disulfide bond stabilizes a globular
structure of FRα. They also identified a deep open folate-binding pocket formed by amino acids
which is conserved across receptor subtypes. The inner portion of the binding pocket
accommodates the pteroate moiety and the glutamate of the folate extrudes as a solvent exposed
moiety. The solvent exposure enables the glutamate moiety to contain conjugated drugs without
hampering the receptor binding of folate. Melcher and coworkers25 also described the amino acid
interaction between the binding pocket and folic acid. The pterin N1 and N2 atoms of folic acid
form strong hydrogen bonds with the side-chain carboxyl group of Asp81, the N3 and O4 atoms
10

with the Ser174 hydroxyl group, the O4 atom forms two hydrogen bonds with the guanidinium
groups of Arg103 and Arg106, and the N5-atom forms one hydrogen bond with the His135 side
chain. The folic acid aminobenzoate is stabilized by hydrophobic interactions with Tyr60, Trp102
and Trp134, which line the middle of the long ligand binding pocket. Extensive interactions are
also observed for the glutamate group, which engages six hydrogen bonds, contributed by the side
chains of Trp102, Lys136 and Trp140, as well as by backbone interactions with His135, Gly137
and Trp138.25 The antifolates methotrexate and aminopterin (Figure 4) contain an amino group
instead of the O4 which results in the loss of hydrogen bonds between that atom and Arg103 and
Arg106 (due to steric clash). This explains why the 4-amino compounds demonstrate low affinity
for FRα.25
In 2013, the crystal structure of FRβ was published by Charles E. Dann III and coworkers.3
The group studied FRβ under neutral and acidic pH conditions and reported six different
conformations. Their work shows the pH dependence of folate binding via structural
rearrangement. The transport and non-transport of folate in neutral vs. acidic pH is explained by
the discovery that the cleft of the receptor goes from open to closed conformation when pH goes
lower.3
2.2.2. FRs: distribution
The apical membrane of polarized epithelial cell lines are the major expression sites for
FRα. hFRα has been identified in several organs: in the choroid plexus region of the brain and in
the proximal tubule region of the kidney. The receptor has also been identified in retina, placenta
and uterus. It is important to note that the expression of FRα in apical surfaces makes the receptor
inaccessible to systemic circulation and as such to circulating folates. Thus the site specificity of

11

FRα provides a natural protection against the cytotoxicity of FRα-targeted chemotherapeutic
agents. FRβ expression is also site specific and the receptor has been observed in myelomonocytic
hematopoietic cells, thymus, placenta and spleen. The expression in hematopoietic cells is not
ubiquitous: monocytes contain FRβ (CD co-expressed) but CD34+ normal hematopoietic
progenitors do not.26 Low level secretion of hFRγ has been observed in lymphoid cells at several
sites: spleen, thymus, and bone marrow. Site specificity of FRα and FRβ, low expression of FRβ
and transcytosis absorption mechanism utilized by FRα gives these receptors unique advantage
compared to RFC as drug targets. These characteristics reduce the dose limiting toxicity of FR
targeted antifolates that have relatively low or no transport via RFC that is otherwise observed in
currently marketed non-specific antifolate drugs.
Along with its site specific expression under normal physiological condition, FRα has also
been observed in several malignant tissues: non-mucinous adenocarcinomas of ovary, uterus and
cervix, and ependymal brain tumors. Positive correlation between FRα level and malignancy stage
and grades has been identified.31 FRβ has also been found in several malignant tissues: chronic
myelogenous leukemia (CML) and acute myelogenous leukemia (AML) [but not Acute
Lymphoblastic Leukemia (ALL)]. The identification that the FRα and FRβ expressed in the
malignant tissues are functional makes them a suitable target for cancer imaging and
chemotherapeutic antifolates.26
2.2.3. FRs: transport
FRs internalizes folates via endocytosis process. Binding of a folate molecule on the cell
surface folate receptor triggers conformational change in the receptor that initiates invagination in
the plasma membrane. At the site of folate binding, the invagination produces a vesicle (endosome)
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and then the vesicle internalizes to start its migration into the cytoplasm.12, 27-29 The pH inside the
endosome reaches 6.0 to 6.5 when it is in the cytoplasm and the acidification causes
conformational change in the FR-substrate complex. This conformational change stimulates the
dissociation of the folate form the receptor and the ligand then follows a trans-endosomal pH
gradient to release into the cytoplasm. The folate releasing endosome returns to the plasma
membrane to get fused with it and thus FR gets back to the initial apo-state. This recycling of the
FR enables the receptor to repeat its transporting activity.12, 27-29
2.2.4. FRs in chemotherapy
Due to their selective expression and high affinity toward reduced folates, FRs are
attractive target for selective anticancer drugs. As mentioned earlier, FRα is overexpressed in
different malignant tissue and in almost all ovarian cancer tissue (90%). In ovarian cancer,
association has been identified between status and grade of the malignancy and FRα expression
level.30 FRβ expressed in myeloid leukemia cells, are capable of transporting folates unlike the
FRβ expressed in normal hematopoetic tissue.31 FRs have been targeted via several cytotoxic
agents: antifolates, folate-conjugates, radionuclides etc.; however, most of these have
demonstrated to be non-selective methods.31 The currently used folate targeted agents (e.g. MTX,
RTX and PMX) are also transported by RFC, which makes them cytotoxic to normal cells. Folate
and pteroate conjugated prodrugs (e.g. mitomycin C conjugate), which are unlikely to bind with
RFC, have been designed to circumvent the selectivity problem, but these drugs have not proven
to be much successful due to their premature cleavage. The early release of cytotoxic moiety before
internalization results in reduced therapeutic effect towards malignant cells and increased toxicity
towards normal proliferating cells. Even if these molecules are internalized, their intracellular
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cleavage generates free folates that feeds the tumor cells as a nutrient. Folate analogs which target
FRs and are themselves cytotoxic will be able to circumvent the two challenges stated here.
2.3. The proton-coupled folate transporter (PCFT)
The PCFT encoding gene was identified on chromosome 17q11.2 and the protein was
discovered in 2006. A member of the solute transfer superfamily of proteins, PCFT absorbs folates
in the upper intestine. The optimum pH for PCFT activity is acidic (pH 5.5) and as such it can
transport folates into non-intestinal tissue when the microenvironment is acidic. PCFT acts as a
proton symporter, transporting folates down an electrochemical concentration gradient along with
protons. Along with its acidic activation pH, substrate specificity of PCFT differentiates it from
the ubiquitous folate transporter RFC. It has been reported that PCFT shows high affinity for folic
acid and low affinity for PT523 (a non-polyglutamable aminopterin analog), contrasting the
opposite affinity pattern demonstrated by RFC.13, 32-33
2.3.1. PCFT: structure
Via immunofluorescence analysis of hemagglutin (HA)-tagged hPCFT molecules it has
been identified that the hPCFT is a 459 amino acid long protein which composes of 12
transmembrane domains.34-36 PCFT does not require to be N-glycosylated to function as a
transporter.31
2.3.2. PCFT: expression
Although PCFT has been identified in several organs: placenta, kidney, liver, retina and
brain, the major expression site is the intestine (specially the duodenum and upper jejunum
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portion). In the acidic microenvironment of its upper intestinal expression sites, PCFT constitutes
the major dietary folate absorbing mechanism.13
2.3.3. PCFT: transport
PCFT medicated folate transport is an electrogenic process, meaning a net translocation of
positive charge takes place. PCFT is a symporter protein that couples uphill flow of folates with
the downhill flow of protons. In accordance with a proton-coupled process, greater unidirectional
folate transport and significant transmembrane folate concentration gradient is resulted by
transvesicular pH gradient. A striking feature of PCFT is its optimal activation at an acidic pH,
while almost total inactivation occurs at physiological pH. Maximum transportation of folates by
PCFT occurs at pH 5 to 5.5 and the activity gradually decreases with increased pH; almost no
activity is detected above pH 7.33-35
2.3.4. PCFT in chemotherapy
The microenvironment of human solid tumor tissue is mostly acidic.36-37 Since hPCFT is
expressed in a broad range of solid tumors, this acidic microenvironment facilitates folate transport
via PCFT.36-38 Although complete understanding of PCFT transport is still in an ongoing stage,
classical antifolate transport by this receptor has been reported in the literature.34 Among classical
antifolates, MTX, RTX, PMX show cytotoxic activity at physiological pH but MTX and RTX
loses the activity at lower pH. PMX still shows cytotoxic activity at lower pH because unlike MTX
and RTX, this molecule is transported by both RFC and PCFT.14, 39 The dose limiting toxicity of
PMX is generated from its dual transport by RFC and PCFT at regular physiological pH. As such,
antifolate designed to be transported by only PCFT and not by RFC will be able to circumvent

15

toxicity to normal tissue. It is important to note that most solid tumors have an acidic
microenvironment (pH 6.0 – 6.8) where only PCFT transports folates and antifolates efficiently.
3. Glycinamide-ribonucleotide formyltransferase (GARFTase)
The de novo synthesis and salvage pathways are two synergistic purine synthesis processes
that generate nucleotides necessary for nucleic acid synthesis and metabolism. Targeting enzymes
involved in these pathways may be a route to gain anti-proliferative effects. There are six
multifunctional enzymes that take part in the 10 step purine de novo biosynthesis. Three of these
six enzymes are mono functional, two are bifunctional and one is trifunctional. Conversion of
phosphoribosyl pyrophosphate to inosine monophosphate occurs in this biosynthesis process.
The trifunctional peptide glycinamide ribonucleotide formyltransferase (GARFTase),
which modulates purine biosynthesis, was first reported by Warren and Buchanan.40 The three
functional parts of this peptide are: glycinamide ribonucleotide synthetase (GARSase), GARFTase
and aminoimidazole ribonucleotide synthetase (AIRSase) and they catalyze the second, third and
fifth steps of the biosynthesis process respectively. The C-8 of inosinic acid (IMP) is incorporated
by GARFTase. In the catalytic process, GARFTase removes a formyl group from N10-formyl-THF
to produce tetrahydrofolate and transfers the formyl to glycinamide ribonucleotide (GAR) to
produce formylglycinamide ribonucleotide (fGAR). Because of its mechanistic role in formyl
transfer,41-42 and biological role in nucleic acid precursors synthesis,43

GARFTase is of

considerable interest as a cytotoxic target.
In RNA and DNA biosynthesis, purine nucleotides act as building blocks. This makes the
de novo purine biosynthetic pathway enzymes viable targets for chemotherapeutic agents. This
potential was demonstrated by the mechanism of action of the cytotoxic agent 5,1016

dideazatetrahydrofolate, which inhibits de novo purine biosynthesis via the inhibition of
GARFTase.44
3.1. GARFTase: structure
hGARFTase is part of a 110 kDa trifunctional peptide that also catalyzes two other steps
in the purine biosynthesis pathway.45 With its natural substrate β-GAR (2.2 Å), hGARFTase has
been studied at pH 4.2 (1.7 Å), pH 8.5 (2 Å) and pH 8.5.46 At near physiological pH, hGARFTase
has been studied with different inhibitors in the bound state. These inhibitors include 10trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-CF3CO-DDACTHF) (2 Å)47
and several other antifolates.48 The X-ray crystal structures of hGARFTase bound with PMX and
similar 6-substituted pyrrolo[2,3-d]pyrimidines has also been reported.49
3.2. GARFTase: catalysis
The catalytic mechanism of GARFTase has been elucidated via a series of kinetic studies
performed on E. coli, human and murine sources. These studies show the formation of a tetrahedral
structure through the nucleophilic attack of the GAR amino group on the formyl carbon of the cosubstrate in the catalytic pocket. It has been proposed that, the proton transfer required for the
formation and collapse of this tetrahedral intermediate is medicated by a water molecule.50
During cofactor binding, the Asp144 of hGARFTase forms a salt bridge with the
imadozolium of His108 and the substrate formyl group is hydrogen bonded with the protonated
imadozolium of His108 and Asn106. The GAR attacks the activated formyl group with its free
base amino group and forms the tetrahedral intermediate. A catalytic water molecule, hydrogen
bonded to the carboxylate of Asp144, mediates proton transfer from GAR to the N10 of folate
which leads to the collapse of the tetrahedral intermediate. The scheme is shown in figure 6.42
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Figure 6. Catalytic mechanism of GARFTase.42
3.3. GARFTase: inhibitor binding
The crystal structure of hGARFTase at pH 7 was resolved by Zhang et al.47 at 1.98 Å as a
binary complex with the inhibitor molecule 10-CF3CO-DDACTHF (PDB entry 1NJS). The crystal
structure showed that the substrate binding pocket of hGARFTase is composed of three domains:
the pteridine binding cleft, the benzoylglutamate binding region, and the formyl transfer region.
Pteridine Binding Cleft. Similar to the N10-formyl-5,8,10-trideazafolic acid (N10-formylTDAF) binding in the E. coli GARFTase complex (PDB entry 1C2T), the diaminopyrimidinone
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portion of 10-CF3CO-DDACTHF is deeply buried in the active site cleft of hGARFTase.
Compared to N10-formyl-5,8,10-trideazafolic acid, 10-CF3CO-DDACTHF shows more flexibility
during binding due to the absence of a fused benzene ring. Thus this monocyclic analog can adapt
relatively easily at the binding site to facilitate gem-diol interaction with the protein. The N2 of 10CF3CO-DDACTHF is within hydrogen bonding range (3.1 Å) of the backbone carbonyl oxygen
of Glu141, because of its relatively higher tilt (15°) compared to the quinazoline ring of N10-formyltrideazafolic acid. The quinazoline ring of N10-formyl-trideazafolic acid, mimics the
diaminopyrimidinone ring of 10-CF3CO-DDACTHF, conserves all the key interactions and
engages in additional hydrogen bonding in the binding site. Several hydrophobic amino acids in
the binding site (Leu85, Ile91, Leu92, Phe96, and Val97) forms a deep pocket to hold the
diaminopyrimidinone. Six hydrogen bonds are formed between the diaminopyrimidinone ring and
the amides and carbonyl residues of several binding pocket amino acids (Arg90, Leu92, Ala140,
Glu141, and Asp144). Two additional hydrogen bonds

are formed between the

diaminopyrimidinone and two ordered water molecules (W18 and W70). The N8 nitrogen of 10CF3CO-DDACTHF forms hydrogen bonds with the carbonyl oxygen of Arg90 and an ordered
water molecule (W70).
Glutamic Acid Tail. In the GARFTase bound 10-CF3CO-DDACTHF complex, two amino
acids, Ile91 and Ser118, forms a hydrophobic pocket to accommodate the p-aminobenzoate portion
of the inhibitor. The carbonyl group and the phenyl ring remain in the same plane. The paminobenzoate is on a perpendicular plane whereas, the aliphatic linker is on a parallel plane
relative to the aliphatic stem of the diaminopyrimidinone ring. Although the glutamate moiety is
solvent exposed, its structure is relatively well-ordered in the enzyme bound state. The Arg64
moiety of the enzyme forms a salt bridge (2.7 Å) with the α-carboxylate of the glutamate, thus
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forcing the γ-carboxylate to orient toward the solvent. The α-glutamate carboxylate forms a
hydrogen bond with the Ile91 moiety as well (2.8 Å).
Formyl Transfer Region and the Gem-Diol Structure. Similar to the transformation of N10formyl-trideazafolic acid in the E. coli GARFTase (PDB 1C2T) bound state, the trifluoromethyl
ketone of hGARFTase bound 10-CF3CO-DDACTHF has been identified to be converted into a
gem-diol. The formyl transfer region of the enzyme shows extensive interaction with the gem-diol
of the inhibitor. The Asp144 of the formyl transfer region forms hydrogen bonds (2.5 and 2.7 Å)
with both the hydroxyls of the gem-diol via its carboxylate group. Another amino acid moiety,
His108, forms hydrogen bonds in a similar fashion with both the hydroxyl groups (2.7 Å and 3.1
Å) using the N3 of its imidazole ring. The backbone carbonyl oxygen of Gly117 forms an
additional hydrogen bond with one of the diol-hydroxyl group.
3.4. GARFTase: inhibitors
Some representative GARFTase inhibitors with bicyclic scaffold are reviewed and listed
in Table 1.
3.4.1. GARFTase inhibitors: 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydropyrimido[5,4-b][1,4]thiazines
Lometrexol. Synthesized by Taylor and coworkers51 in 1985, lometrexol (LMTX, Table 1)
was the first GARFTase inhibitor to reach the clinical trial stage. LMTX is the 6-(R)-isomer of the
compound 5,10-dideazatetrahydrofolic acid (DDATHF). The discovery of lometrexol was the first
step in establishing GARFTase and the de novo purine biosynthesis as a potential target for
anticancer chemotherapy. Although lometrexol showed poor effect on DHFR and TS, it was a
substrate for PFGS and a potent inhibitor of GARFTase (Ki = 6 nM).52 Among the equipotent
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diastereomers of 5,10-dideazatetrahydrofolic acid, the one mimicking the tetrahydrofolates, the
(6R)-diastereomer, was taken further in the development process. Despite its demonstrated potency
GARFTase inhibitors: 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8dihydro-pyrimido[5,4-b][1,4]thiazines (Table 1)
Structure
Compound Biological
Ref.
Activity
LMTX
(6-(R)DDATHF)

hGARFTase (Ki)
6 nM

52

LY-222306
(6-R,S)

hGARFTase (Ki)
0.77 nM

53

CCRF-CEM
(IC50)
27 nM
LY-254155
(6-R,S)
LY-309887
(6-R)

hGARFTase (Ki)
2.1 nM

AG-2034

hGARFTase (Ki)
28 nM

54

CCRF-CEM
(IC50)
27 nM
55

CCRF-CEM
(IC50)
2.9 nM
AG-2037
(pelitrexol)

hGARFTase (Ki)
0.5 nM

56

LMTX showed severe toxicities (myelosuppression and mucositis) in phase I trials. The nonselective transport of LMTX by both RFC and FRs have been identified as the cause of its
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cumulative toxicity. Indiscriminate absorption and accumulation results in the increased cellular
concentration of the drug in both normal and malignant cells that causes cytotoxicity.57
LY-309887. A novel class of classical antifolates were synthesized by Habeck et
al.53 in which the 1’,4’-phenyl group of LMTX was replaced with a 2’,5’-furan (LY-222306) and
a 2’,5’-thiophene (LY-254155) (Table 1). Both compounds, LY-222306 and LY-254155, as
mixtures of diastereomers were found to inhibit the growth of CCRF-CEM cell line (IC50 = 27 nM
and 2.3 nM, respectively) and were inhibitors for hGARFTase (Ki = 0.77 nM and 2.1 nM,
respectively). Resolution and testing of diastereomers revealed the compound 6R-2’,5’-thienyl5,10-dideazatetrahydrofolic acid (LY-309887, Table 1) to be more potent than LMTX in murine
C6H mammary tumor model and in several xenografts. LY-309887 was 9-times more potent than
LMTX against GARFTase and was more active against two pancreatic xenografts and in the
human LX-1 lung carcinoma model. However, similar to LMTX, LY-309887 showed cumulative
toxicity in phase I clinical trials attributable to nonselective transport via RFC into normal cells.
AG-2034 and AG-2037. AG-2034 (Table 1) is a compound structurally similar to LY309887 (Table 1), which was designed using the x-ray crystal structure of GARFTase.55 AG-2034
is a potent inhibitor of hGARFTase with Ki = 28 nM and the molecule is transported by FRs more
effectively than LMTX. AG-2034 inhibited L1210 and CCRF-CEM cell lines (IC50 = 4.0 nM and
2.9 nM, respectively) and showed in vivo antitumor activity in lung carcinomas, lymphosarcomas,
mammary and colon adenocarcinomas and melanoma. AG-2034 did not show the cumulative
myelosupressive effect of LMTX, but did show mucositis and diarrhea in phase I clinical trial. 58
Another LMTX analog AG-2037 (pelitrexol, Table 1), has the configuration reversed at C-6
compared to LMTX. Unlike AG-2034, it contains a pyrido[2,3-d]pyrimidine scaffold (same as
LMTX) and methylated thiophene in the sidechain. AG-2037 demonstrated potent antitumor
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activity in several in vitro and in vivo studies and proved to be a potent GARFTase inhibitor (Ki =
0.5 nM). AG-2037 was determined to be well tolerated in several phase I trials and phase II trial
on advanced metastatic colorectal cancer patients was conducted.59-60 However, development of
the molecule was discontinued due to a lack of single agent efficacy.60
3.4.2 GARFTase inhibitors: FRα- and PCFT-substrates49, 61-64 (Table 2)
Cmpd.

Structure

RFC

FRα

PCFT

KB

KB

IC50 in
nM

IC50 in
nM

IC50 in nM

IC50 in nM

PC43-10

RT16

R2/hPCFT4

KB(RFC/FRα/PCFT)

(+Thd/Ade/
AICA)

11

6-pyrrole/3C/phenyl

648.6
(38.1)

4.1 (1.6)

23.0 (3.3)

1.7 (0.4)

Ade/AICA

12

6-pyrrole/4C/phenyl

>1000

6.3 (1.6)

213 (28)

1.9 (0.7)

Ade/AICA

13

5-pyrrole/2C/phenyl

30.6 (6.2)

18.2
(3.8)

22.3 (8.6)

9.94 (3.11)

Thd/Ade

14

5-pyrrole/3C/phenyl

68.8
(21.2)

72.0
(27.1)

329 (61)

49.5 (13.2)

Ade

4

5-pyrrole/4C/phenyl

56.6 (5.8)

8.6 (2.1)

840 (90)

12.7 (5.4)

Ade

16

6- pyrrole /3C/thieno

101.0
(16.6)

0.31
(0.14)

3.34 (0.26)

0.26 (0.03)

Ade/AICA
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6- pyrrole /4C/thieno

>1000

1.82
(0.28)

43.4 (4.1)

0.55 (0.10)

Ade/AICA

18

5- pyrrole /3C/thieno

116.0
(22.5)

109 (44)

312 (90)

211 (58)

Ade

5

5- pyrrole /4C/thieno

38.3 (6.6)

49.3
(11.5)

141 (40)

66.0 (14.4)

Ade

(PMX)

Novel 5-substituted and 6-substituted classical pyrrolo[2,3-d]pyrimidine antifolates with
anti-tumor activity have been reported by Gangjee and coworkers49,
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61-64

(Table 2). These

molecules comprise of a varying array of aliphatic and/or aromatic groups in the side chain linker.
Among the 6-substituted compounds, the 3- and 4- carbon chain analogs showed the most potent
inhibition against KB and IGROV1 tumor cell lines.49, 61-62

Figure 7. Representative 5-substituted and 6-substituted pyrrolo[2,3-d]pyrimidines
with only GARFTase inhibition or GARFTase/AICARFTase dual inhibition.49, 63-64
In vitro studies on FR expressing CHO cells revealed that most of the 6-substituted
compounds with a phenyl or a thiophene group on the side chain are FR selective over RFC, while
the corresponding 5-substituted compounds are not selective. The shorter linker length (2C to 4C
for phenyl and 2C to 5C for thiophene) in the 5-substituted compounds are usually associated with
PCFT activity.49, 63-64 The protection studies indicated that 6-substituted sidechain phenyl and
thieno compounds are mainly GARFTase inhibitors, whereas 5-substituted 3C/4C sidechain
phenyl and thieno compounds are mainly GARFTase/AICARFTase dual inhibitors.
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II. CHEMICAL REVIEW
Several five and six membered heterocycles have been identified to have biological activity
and among them pyrrolo[2,3-d]pyrimidines are a notable group. Due to their structural similarity
with purines and folate metabolites, different pyrrolo[2,3-d]pyrimidine compounds have been
synthesized and biologically evaluated. In this section, procedures to synthesize pyrrolo[2,3d]pyrimidine reported in the existing literature has been discussed in detail. The three major
approaches to synthesize 5-substituted, 6-substituted and 5,6-disubstituted pyrrolo[2,3d]pyrimidines are: 1) from pyrimidine precursors, 2) from pyrrole precursors and 3) from furan
precursors, which are discussed.
1. Pyrrolo[2,3-d]pyrimidine from pyrimidine
In the literature pyrimidine has been described as the main precursor of pyrrolo[2,3d]pyrimidines.

Scheme 1. Synthesis of pyrrolo[2,3-d]pyrimidines 28.
The synthesis of 6-substituted 2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one 28
(Scheme 1) from 1,3-dioxolane-2-propanoic acid, α-cyano-2-methyl-ethyl ester 25 and guanidine
26 was first reported by Seela and Luekpke. 65
The synthesis of unsubstituted pyrrolo[2,3-d]pyrimidines 31 (Scheme 2) and 34 by the
reaction of chloroacetaldehyde 30 with 2-amino-6-alkylamino-4-hydroxypyrimidines 29 and 6amino-1,3-dimethyluracil, 32 respectively was first reported by Noell and Robins.66
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Scheme 2. Synthesis of pyrrolo[2,3-d]pyrimidines 31 and 34
The synthesis of pyrrolo[2,3-d]pyrimidine with trifluoromethyl substitution (Scheme 3)
was reported by Gibson et al.67 They reported the reaction of the oxime of bromotrifluoroacetone
36 with 35 (excess) in DMF to afford the C-5 alkylated pyrimidinone 38 in 80% yield.

Scheme 3. Synthesis of 8-trifluoromethyldeazaguanine 38.

Scheme 4. 5-Substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidine 41, 42 and 43.
5,6-Disubstituted-pyrrolo[2,3-d]pyrimidine was also synthesized by Gibson et al.67 2Chloro-2-cyanoethanal 40 was reacted with 39 (Scheme 4) to afford exclusively the 7-yano-726

deazaguanine 41. Substituents at C-5 and C-6 were obtained by brominating the primary
deazaguanine 41 with N-bromosuccinimide in DMF to afford the 7-cyano-8-bromo derivative 42.
These transformations established methods for the synthesis of a wide range of 5-substituted, 6substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidines.

Scheme 5. Synthesis of pyrrolo[2,3-d]pyrimidines 48 and 50 and furo[2,3-d]pyrimidines 47.
A detailed study of the reaction of 2,6-diamino-4-hydroxypyrimidine 44 (Scheme
5) with various -halo aldehydes and ketones was reported by Secrist and Liu.68 They reported
that the cyclization occurred via one of two modes to produce either the pyrrolo[2,3-d]pyrimidine
and/or the furo[2,3-d]pyrimidine. Thus -halo ketones, chloroacetone 45 and 3-bromo-2-butanone
46, afforded both the furo[2,3-d]pyrimidine 4 and the pyrrolo[2,3-d]pyrimidine 47, whereas 49
produced only the pyrrolo[2,3-d]pyrimidine 50 on reaction with 44. They suggested that to
exclusively afford pyrrolo[2,3-d]pyrimidines, a critical electron density is necessary for the C5 of
the pyrimidine nucleus to react with the -carbon atom of the -halo aldehydes or ketones.
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Scheme 6. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57.
Taylor et al.69 reported a synthetic scheme for 6-substituted pyrrolo[2,3-d]pyrimidines.
Chloromercuration of 2-pivaloylamino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidine yielded a 10:l
mixture of the 6-chloromercuri derivative 52 and the 5-chloromercuri derivative 53 in 74% overall
yield (Scheme 6). Without separation, this mixture of chloromercuri derivatives were treated with
iodine in dichloromethane to give the corresponding iodo derivatives (54 and 55) from which the
desired 6-iodo compound 54 was readily separated in 64% yield by column chromatography. A
palladium- catalyzed carbon-carbon coupling reaction of this 6-iodopyrrolopyrimidine derivative
54 with dimethyl 4-ethynylbenzoyl-L-glutamate 56 led to the C-6 coupled derivative 57 in 78%
yield.
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Scheme 7. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 57 and 60.
Another scheme for functionalizing the 6-position of pyrrolo[2,3-d]pyrimidine was
reported by Taylor et al.70 A more efficient synthesis of 57 resulted from the use of an
ethoxycarbonyl N-7 protecting group rather than an N-Ts group (Scheme 7).

Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidine 62 from 6-amino-5-pyrimidylacetaldehydes 61.
A novel synthetic approach for PMX (Scheme 8) was described by Taylor et al.70 in which
spontaneous cyclization of sodium 4-[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-4nitrobutyl]benzoate 61 occurred. Conversion of acid 62 to PMX involved standard peptide
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coupling with diethyl L-glutamate using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the coupling
agent in presence of N-methylmorpholine and final saponification.

Scheme 9. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization.
Fisher indole cyclization of 6-(phenylhydrazino)uracil 63 to 9H-pyrimido[4,5-b]indole2,4-dione 64 (Scheme 9) was reported by Wright et al.71 Several authors have employed the Fischer
indole cyclization of 4-pyrimidinylhydrazones 65 (Scheme 9) to afford the pyrrolo[2,3d]pyrimidine ring system 66. The applicability of the Fischer-indole cyclization to the synthesis of
pyrrolo[2,3-d]pyrimidines, however is limited by the high reaction temperatures and the steric
constraints for the [3,3] sigmatropic rearrangement involved in the mechanism.

Scheme 10. Synthesis of pyrrolo[2,3-d]pyrimidine 78.
A synthetic scheme for the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine
(Scheme 10) had been reported by Gangjee and coworkers.72 Compound 73 and guanidine
carbonate at reflux in absolute ethanol in the presence of triethylamine or sodium methoxide
afforded 74. Compound 74 was converted to 75 with phosphorus oxychloride at reflux in 68%
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yield. Condensation of benzylamine with 75 in the presence of triethylamine under reflux in nBuOH afforded the bicyclic compound 76 in 50% yield. Compound 76 was oxidized to aromatic
compound 77 using MnO2. Sodium in liquid ammonium at -78 °C afforded the debenzylation of
77 to 78.

Scheme 11. Synthesis of pyrrolo[2,3-d]pyrimidines 82.
Protected 5-acetaldehyde pyrimidine 81 was subjected to intramolecular cyclization to synthesize
pyrrolo[2,3-d]pyrimidine 82 (Scheme 11) by Sakamoto and coworkers.73 Compound 81 were
synthesized by palladium(0) catalyzed coupling of the appropriate 2,4-disubstituted-5-bromo-6acetamido pyrimidine 79 with (Z)-1-ethoxy-2-(tributylstannyl)ethane 80. The same methodology
was used for the synthesis of pyrrolo[3,2-d]pyrimidines.
2. Pyrrolo[2,3-d]pyrimidine from pyrrole

Scheme 12. Synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 87.
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4-Amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 87 (Scheme 12) was synthesized by
Taylor et al.74 Tetracyanoethylene 83 was converted by the action of hydrogen sulfide to 2,5diamino-3,4-dicyanothiophene 84, which was rearranged with alkali to 5-amino-3,4-dicyano-2mercaptopyrrole 85 as described by Middleton et al.75 Treatment of 85 with methyl orthoformate
followed

by

alcoholic

ammonia

gave

4-amino-5-cyano-6-methylmercaptopyrrolo[2,3-

d]pyrimidines 86. Raney nickel desulfurization of 86 then gave 87.

Scheme 13. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 92.
Taylor et al.76 also reported the synthesis of 4-amino-5-methyl-pyrrolo[2,3-d]pyrimidine 92 (R =
CH3) (Scheme 13) from 2-amino-3-cyano-4-substituted pyrroles 92 which in turn were obtained
from malonodinitrile and the appropriate -aminoketones 88. Treatment of pyrrole 90 with
triethylorthoformate followed by ammonia resulted in the imidine intermediates 91 which
underwent cyclization with sodium methoxide in pyridine to afford the pyrrolo[2,3-d]pyrimidine
92.
A 5,6-dihydro-pyrrolo[2,3-d]pyrimidine analog of PMX was synthesized by Taylor and
coworkers77 (Scheme 14). A manganic triacetate dihydrate mediated radical cyclization of racemic
methyl N-crotyl-N-[1-(3,4-phenyl)-eth-1-yl)malonamide 97, afforded a diastereomeric mixture of
the 3-carbomethoxy-2-pyrrolidinone 98. Compound 97 was in turn obtained by alkylation of
racemic 1-(3,4-dimethoxy-phenyl)-ethylamine 93 with crotyl bromide 94 followed by a DMAP
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catalyzed acylation with methyl malonyl chloride 96. The pyrrolidinone 98 was converted to the
thiolactam 99 with P2S5 followed by cyclocondensation with guanidine to afford the N7-protected
5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 100. Palladium catalyzed cross-coupling with
diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded the ethano-bridged derivatives, and not
the expected vinyl-bridged derivatives, by double bond migration. This compound was then
elaborated to analogs of PMX.

Scheme 14. Synthesis of N7-substituted analogs of PMX.
Utilizing a guanidine cyclization of a preformed 3-carbethoxy-2-thiopyrrolidine
intermediate 105 (Scheme 15) as the key step, Barnett et al.78 reported the synthesis of a 2-amino4-oxo-5,6-dihydropyrrolo[2,3-d]pyrimidine 106. This intermediate was in turn prepared over
several steps from 4-propionaldehyde benzoic acid tert-butyl ester 101. Compound 106 was
reduced to the pyrrolo[2,3-d]pyrimidine intermediate, 107 which was then elaborated to PMX in
several steps.
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Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidine 107 and PMX.
3. pyrrolo[2,3-d]pyrimidines from furans

Scheme 16. Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 110.
Taylor and coworkers79 reported an unexpected ring transformation/ring annulation
sequence in which 2-amino-3-cyanofurans 108 (Scheme 16) on cyclization with amidines 109
afforded the corresponding pyrrolo[2,3-d]pyrimidines 110.
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III. STATEMENT OF THE PROBLEM
The idea of selective tumor targeting using FRs has been discussed in the literature.
However, the concurrent transport of antifolate ligands by RFC, foils the practical application of
this approach. For that reason, avoiding the RFC transport of the ligands and targeting FR is a
prime objective to attain selectivity in antifolate therapy. PCFT specific ligand development is
another approach that has potential for selectivity. Combining these two concepts, an antifolate
which is transported by FRs and/or PCFT over RFC and targets intracellular enzymes (e.g.
GARFTase, AICARFTase) is the desired molecule to be designed as a potential selective
anticancer agent.
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoyl)-Lglutamic acid and its analogs with variation in the chain length and/or side chain aromatic
group as GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC:

Figure 8. The structures of classical 2-amino-4-oxo-5-substituted pyrrolo[2,3d]- pyrimidine antifolates 4 and 5 (Table 2).
At physiological pH, RFC dominantly transports the anionic folate analogs into the cell.
Tissue specific FRs (FRα and FRβ) performs endocytosis to transport folates into the cell in the
tissues where they are expressed (e.g. FRα in kidney, choroid-plexus and several malignancies
including 90% of ovarian cancer; FRβ in placenta, spleen, and thymus) and functions at
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physiological pH.26, 29, 80 The site restrictive expression of FRs make them potential mechanisms
for tissue selective drug transport. In contrast to these two types of folate transporters, PCFT
transports folates predominantly at acidic pH, which usually is the microenvironment in and
around solid tumors.29, 81 Due to its expression being restricted in the apical brush border of the
proximal tubule of the kidney, FRα does not cause renal toxicity that might otherwise have resulted
by classical antifolates. Although FRβ expression occurs both in normal hematopoietic cells and
myeloid leukemia cells, only those proteins expressed in malignant cells can bind folate analogs.31,
82

PCFT only transports folates in the acidic environment of the small intestinal expression site;

but does not transport in the kidney or liver due to the lack of an acidic environmnet.11 In study of
solid tumor cell lines, 29 out of 32 cell lines demonstrated transport at acidic pH, which is
conducive to PCFT transport.1
Different approaches to utilize FR transport of folates has been studied as targeted
anticancer therapy which includes: folate-conjugates, radionuclides, antifolate cytotoxins etc.4, 8385

One technique to take advantage of the high affinity of FRs for folic acid was to attach an active

compound with folic acid, thus using the folic acid as the targeting component.86-87 Delivery of
antisense oligonucleotides and radioactive compounds used for therapy and imaging has also been
performed using this method.88 However in most of the cases tumor selectivity was not attained.
The clinically available classical antifolate PMX inhibits KB cell line (IC50 9.94 nM), as
well as FRα (IC50 18.2 nM) and PCFT (IC50 18.2 nM) expressing CHO cell lines. However, PMX
is also transported by RFC (IC50 30.6 nM) and thus lacks FRα and/or PCFT selectivity over RFC.
Research has revealed that TS is the primary target of PMX, not GRAFTase.85 Novel classical
antifolates 4 and 5 (Figure 8), with a pyrrolo[2,3-d]pyrimidine scaffold and 5-substitution, has
been reported by Gangjee and coworkers63-64 which are GRAFTase inhibitors. These compounds
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with varying lengths of carbon linker side-chains have been shown to possess potent KB cell
inhibitory activity, which has been ascribed to their ability to be transported via FRs (FRα and
FRβ) and RFC. Among the 5-substituted compounds, those with 4-carbon linker chains and a
phenyl (4) or thiophene (5) ring (Figure 8) in the side chain showed significant inhibitory activity
against CHO cell lines expressing FRα. Compound 4 showed FRα selectivity over RFC, but 5 did
not show such selectivity. Protection studies revealed that both 4 and 5 had potent inhibitory effect
on GARFTase. This activity was responsible for disrupting the de novo purine biosynthetic
pathway inside the cell and that was the major mechanism of cytotoxicity. Studies also revealed
that 4 (containing a phenyl in the side chain) possesses some PCFT activity, and the activity
improves significantly for 5 (containing a thiophene in the side chain). Despite the molecules being
potent KB cell inhibitors and FRα substrates, they showed some limitations. Compound 4 showed
limited PCFT activity and 5 did not have selectivity for FRα over RFC.63-64 Thus additional SAR
investigations were warranted to optimize the transport selectivity and retain the anticancer activity
of 5-substituted pyrrolo[2,3-d]pyrimidine compounds.

Figure 9. The structures of proposed classical 2-amino-4-oxo-5-substituted pyrrolo[2,3d]- pyrimidine antifolates 6-10.
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With 4 and 5 as the lead, important SAR variations in the side-chain aromatic group were
proposed. This included substituting the thiophene with a furan, or a substituted phenyl, or a
regioisomer of the 1,4-phenyl; with varying lengths of the aliphatic side-chain as the linker. In the
work reported in this thesis, we investigated the SAR for cellular uptake and inhibitory activities
of the 5-substituted pyrrolo[2,3-d]pyrimidine scaffold of 5, with variations in the length of the side
chain and/or variations in the aromatic group in the side chain. The specific goal was to explore
the SAR for novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 6-10 (Figure 9), related to
the potent and FR selective 5-substituted pyrrolo[2,3-d]pyrimidines 4 and 5, for inhibiting the
proliferation of FRα- and PCFT-expressing tumor cells with substantially reduced inhibitory
effects toward normal RFC expressing cells.
To validate our design effort, molecular modeling was conducted with published crystal
structures. Both FRα and GARFTase, co-crystalized with pyrrolo[2,3-d]pyrimidines, have recently
been reported by Gangjee and coworkers.89-90 The lead 5 and a representative proposed compound
8 (Figure 9) were docked into the reported FRα and GARFTase crystal structures. For all the
docking studies, Schrodinger Maestro 11.4 software package was used. This molecular modeling
provided a molecular level interaction estimate of the receptors and ligands and allowed a
determination of the rank order of bound conformations for each proposed molecule.
Prior to docking 5 and 8, Maestro 11.4 was validated by re-docking the native ligands for
reported GARFTase (AGF183) and FRα (AGF71) co-crystal structures. Figure 10A and 11A
show the docked pose of 5 in the human FRα (PDB 5IZQ) binding site.89 Compound 5 binds in
the same cleft of the co-crystalized ligand AGF183 (PDB 5IZQ). The 2-NH2 and N1 of 5, both
interacts with Asp81 residue in the binding site. The 4-oxo forms hydrogen bonds with the side
chain NH of Arg103. The pyrrolo[2,3-d]pyrimidine scaffold is sandwiched between the side chains
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of Tyr85 and Trp171, similar to that seen with the pteroyl ring of AGF183 in its bound
conformation. The L-glutamate moiety of 5 is oriented similarly to the corresponding glutamate in
AGF183. The α-carboxylic acid of 5 forms a network of hydrogen bonds involving the backbone
NH of Gly137 and Trp138 and the side chain NH of Trp140. The γ-carboxylic acid interacts with
the side chain NH groups of Trp102, as is seen with the corresponding glutamate portion of
AGF183 in the crystal structure. The hydrophobic 4C linker of 5 forms nonspecific hydrophobic
interactions with Tyr60, Phe62, Trp102, and Trp134. The docking score of 5 is -14.46 kcal/mol.
Compared to the docking for AGF183 of -13.23 kcal/mol, the docking score of 5 indicates a better
binding.

Figure 10. Molecular modeling studies of compounds 5 and 8 with FRα. (A) Docked pose of 5
(magenta) in human FRα (PDB 5IZQ).89 (B) Docked pose of 8 (green) in human FRα (PDB
5IZQ).89
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Figure 11. (A) Ligand interaction map of 5 (magenta) in human FRα (PDB 5IZQ).89 (B)
Ligand interaction map of 8 (green) in human FRα (PDB 5IZQ).89
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The docked poses of 8 in human FRα retains the docking interactions of the pyrrolo[2,3d]pyrimidine scaffold and the thienoyl side chain, as seen with the docked pose of 5 (Figure 10B
and 11B). The hydrogen bond between the 4-oxo and the side chain NH of Arg103 is also retained.
There is an additional hydrogen bond between the N3 and Ser174. The α-COOH of glutamate
chain of 8 maintains the network of hydrogen bonds with Trp138, Trp140 and Trp140 similar to
that seen with the α-COOH of the glutamate chain of 5. The γ-COOH also retains the interaction
with the side chain NH groups of Trp102. Unlike 5, a new pi-stacking interaction is observed
between Trp102 and the furan ring of the side chain of 8. Similar to 5, the aliphatic side chain of
8 occupies a hydrophobic pocket formed by Tyr60, Phe62, Trp102, and Trp134. The docking score
of 8 was -13.30 kcal/mol, similar to AGF183, indicating strong potential of binding of 8 to FRα.

Figure 12. Molecular modeling studies of compounds 5 and 8 with GARFTase. (A)
Docked pose of 5 (magenta) in GARFTase (PDB 4ZYV).90 (B) Docked pose of 8 (green) in
GARFTase (PDB 4ZYV).90
Because 5 was identified as a GARFTase substrate in the in vitro protection studies on KB
tumor cells, it was of interest to do comparative molecular modeling of 8 with 5 to identify its (8)
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GARFTase inhibitory potential. Docking of 5 and 8 was conducted using the reported GARFTase
crystal structure(PDB 4ZYV).90

Figure 13. (A) Ligand interaction map of 5 (magenta) in GARFTase (PDB 4ZYV).90
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Figure 13. (B) Ligand interaction map of 8 (green) in GARFTase (PDB 4ZYV).90

Figure 12A and 13A show the docked pose of 5 in the GARFTase active site. Docked pose of 5
was compared with the co-crystalized ligand AGF71 and a flip in the scaffold of 5 was observed
compared to AGF71. The pyrrolo[2,3-d]pyrimidine scaffold of 5 shows interaction of the 2-NH2
of 5 with the backbone of Leu899 and Glu948. The N3 of 5 forms a hydrogen bond with the
backbone of Ala947, the N1 nitrogen forms a hydrogen bond with Leu899, and the 4-oxo moiety
forms hydrogen bonds with the backbone atoms of Asp951. The pyrrole N7 nitrogen forms a
hydrogen bond with the backbone of Arg897. The pyrrolo[2,3-d]pyrimidine scaffold of 5 forms
hydrophobic interactions with Leu899, Val946, Ala947, Val950 and Ala952. The amide NH of
the L-glutamate forms a hydrogen bond with Met896. The glutamate chain of 5 is oriented similar
to the glutamate chain of co-crystalized ligand AGF71 with the α-COOH interacting with Arg871,
and the γ-COOH interacting with Lys844 and a water molecule. The docking score of 5 in
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GARFTase was −10.09 kcal/mol. Figure 12B and 13B show the docked pose of 8 in the GARFTase
active site. The docked pose is similar to that of 5 in GARFTase described above. However, in
case of 8, the γ-COOH of the glutamate flips and results in a loss of Lys844 and water interactions
but replaces the α-COOH’s interactions with Arg871and Ile898. The docking score of 8 in
GARFTase was -13.08 kcal/mol indicating a better binding than 5.

Compounds 6, 7, 9 and 10 were docked in FRα and GARFTase in a similar fashion mentioned
above. The docking score in FRα for 6 was -12.06 kcal/mol, for 7 was -13.46 kcal/mol, for 9 was
-13.20 kcal/mol and for 10 was -13.73 kcal/mol. The docking score in GARFTase for 6 was -9.84
kcal/mol, for 7 was -11.87 kcal/mol, for 9 was -12.59 kcal/mol and for 10 was -12.86 kcal/mol.
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IV. CHEMICAL DISCUSSION
1.

The synthesis of (S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-

yl)butyl)benzoyl)-L-glutamic acid 6.

Scheme 18. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 6.
Reagents and conditions: (a) Pd(CH3COO)2, LiCH3COO, N(C4H9)4Cl, LiCl, 70 C,

4

h,

68%; (b) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (c) 2,6-diamino-4-oxo-pyrimidine, CH3COONa,
MeOH, 45 °C, 12 h, 51% over two steps; (d) (i). 1N NaOH, 45 C, 14 h; (ii). 1N HCl, 77%; (e) NMethylmorpholine,

2-chloro-4,6-dimethoxy-1,3,5-triazine,

L-glutamate

diethyl

ester

hydrochloride, DMF, rt, 6 h, 98%; (f) (i). 1N NaOH, rt, 4 h; (ii). 1N HCl, 46%.
Compound 6 (Scheme 18) was synthesized following a previously reported procedure.63 The key
step in the scheme was the condensation of α-bromoaldehyde with 2,6-diamino-4-oxo-pyrimidine.
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The first step was a Heck coupling reaction of aryl iodide 121 with commercially available
unsaturated alcohol 120 in DMF at 70° C. This reaction afforded the aldehyde 122 (yield: 68%).
As reported by Kanao et al.91, Bromine/1,4-dioxane dissolved in DCM was reacted with the
aldehyde 122 at room temperature to yield α-bromoaldehyde compound 123, which was
immediately used for the following step. Condensation of α-bromoaldehyde 123 with 2,6-diamino4-oxo-pyrimidine at 45 °C in the presence of sodium acetate afforded the 5-substituted pyrrolo[2,3d]pyrimidine 124 (yield 51% over two steps). Subsequent hydrolysis with 1N NaOH (yield: 77%),
followed by coupling with diethyl L-glutamate using N-methyl morpholine and 2,4-dimethoxy-6chlorotriazine as the activating agents, afforded the diester 126 (yield: 98%). Final saponification
of the diester with 1N NaOH afforded the final compound 6 (yield: 46%).
2.

The synthesis of (S)-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-

yl)propyl)furan-2-carbonyl)-L-glutamic acid 7.
For the target compound 7 (Scheme 19), the side chain aryl group is a furan, instead of a phenyl
in 6. For the synthesis of 7, a scheme similar to that used for 6 was employed with a slight
modification. Unlike Scheme 18, where the starting material 121 was an ester, in Scheme 19 an
acid (bromofuroic acid) was used as a starting material. Thus an extra step of hydrolyzing the ester
to acid before glutamate coupling could be avoided and in Scheme 19 the glutamate coupling was
conducted in the very first step. With the starting material 5-bromo-2-furoic acid, diethyl Lglutamate was reacted at room temperature using N-methyl morpholine and 2,4-dimethoxy-6chlorotriazine as the activating agents. This step produced the diester 128 (yield: 89%), which was
subjected to Heck coupling. The diester 128 was reacted with commercially available unsaturated
alcohol 129 in DMF at 70° C for 4 hours. This reaction afforded the aldehyde 130 (yield: 38%).
The aldehyde 130 produced in this step proved difficult to isolate, and yield was substantially
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lower than the same coupling step of Scheme 18. After isolating 130 via multiple CombiFlash
column run (column chromatography), the intermediate was brominated. In the bromination step,
bromine/1,4-dioxane dissolved in DCM was reacted with the aldehyde 130 at room temperature
to yield the α-bromoaldehyde 131, which was immediately used for the next step.91 Condensation
of α-bromoaldehyde 131 with 2,6-diamino-4-oxo-pyrimidine at 45 °C in the presence of sodium
acetate afforded the 5-substituted pyrrolo[2,3-d]pyrimidine 132 (yield 12% over two steps).
Subsequent saponification of the diester 132 with 1N NaOH afforded the final compound 7 (yield:
45%).63

Scheme 19. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 7.
Reagents and conditions: (a) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, Lglutamate diethyl ester hydrochloride, DMF, rt, 12h, 89%; (b) Pd(CH3COO)2, LiCH3COO,
N(C4H9)4Cl, LiCl, 129, DMF, 70 °C, 4 h, 38%; (c) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (d) 2,647

diaminopyrimidin-4(3H)-one, CH3COONa, MeOH, 45 °C, 12 h, 12% over two steps; (e) (i). 1N
NaOH, rt, 2 h; (ii). 1N HCl, 45%.
3.

Alternative scheme for the synthesis of (S)-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-

pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan-2-carbonyl)-L-glutamic acid 7.

Scheme 20. Alternative scheme for the synthesis of 2-amino-4-oxo-5-substitutedpyrrolo[2,3-d]pyrimidine 7.
Reagents and conditions: (a) CuI, PdCl2, PPh3, Et3N, CH3CN, pent-4-yn-1-ol, microwave, 100 °C,
1 h, 58%; (b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 72%; (c) 1N NaOH, rt, 3 h; (ii). 1N HCl, 47%;
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(d) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester
hydrochloride, DMF, rt, 12h, 90%; (e) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3 h,74%, (f)
Br2, 1,4-dioxane, CH2Cl2, rt, 3 h; (g) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa, MeOH,
45 °C, 12 h, 36% over two steps; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 34%.
In an effort to optimize the synthetic scheme and avoid the difficulty of separation in the
Heck coupling step, an alternative coupling was employed to resynthesize target compound 7.
Sonogashira coupling was tried and following the precedence in the literature, an ester was used
as a starting material for this coupling reaction. In this scheme (Scheme 20), a modified microwave
Sonogashira coupling reaction reported by Gangjee and coworkers92 was used as the first step.
Compound 135 was obtained by a Sonogashira coupling of bromofuroate 133 with commercially
available unsaturated alcohol 134 in a microwave reactor at 100 °C for 1 hour (yield: 58%).
Compared to the Heck coupling step of Scheme 19, the yield of coupling product was significantly
improved in Scheme 20 (58% yield in Sonogashira coupling vs. 38% yield in Heck coupling).
Compound 135 was hydrogenated with 55 psi H2 in presence of catalyst palladium on carbon
(yield: 72%) and subsequently hydrolyzed with 1N NaOH at room temperature to afford the acid
137 (yield: 47%). Then 137 was reacted with L-glutamate diethyl ester hydrochloride in DMF to
afford the diester 138 (yield: 90%) using N-methyl morpholine and 2,4-dimethoxy-6chlorotriazine as the activating agents. The alcohol portion of 138 was oxidized with Dess-Martin
Periodinane to the aldehyde (yield: 74%) and then brominated at the α-position to yield 131. The
α-bromoaldehyde 131 was immediately used in the next step for condensation with 2,6-diamino4-oxo-pyrimidine at 45 °C in the presence of sodium acetate to afford the 5-substituted pyrrolo[2,3d]pyrimidine 132 (yield 36% over two steps). Subsequent saponification of the diester 132 with
1N NaOH afforded the final compound 7 (yield: 34%).63
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4.

The synthesis of (S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-

yl)butyl)furan-2-carbonyl)-L-glutamic acid 8.
To optimize the Sonogashira coupling employed in Scheme 20, in Scheme 21, the coupling step
was repeated several times for different durations. Repeating the Sonogashira coupling for 15 min,
30 min and 60 min improved yield consistently but going beyond 60 min produced too many side
products demonstrated by multiple spots in TLC. Yields for the three attempts were 27%, 63% and
79% for 15 min, 30 min and 60 min respectively. The compound 140 obtained from these three
reactions were mixed and subjected to the next reaction. Hydrogenation at 55 psi H2 in presence
of catalyst palladium on carbon (yield: 85%) and subsequent oxidation with Dess-Martin
Periodinane gave aldehyde 142 (yield: 84%). The aldehyde 142 was brominated to yield the αbromoaldehyde 143, which was immediately used in the next step to condense with 2,6-diamino4-oxo-pyrimidine at 45 °C in the presence of sodium acetate to afford the 5-substituted pyrrolo[2,3d]pyrimidine 144 (yield 46% over two steps). Unlike the previous scheme (Scheme 20), in Scheme
21, glutamate coupling was performed at a later step to keep the molecular weight of the
intermediates lower, so that the loss in each purification step remains low. Compound 144 was
hydrolyzed with 1N NaOH at room temperature to afford the acid 145 (yield: 96%). Then 145 was
activated with N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine and reacted with Lglutamate diethyl ester hydrochloride in DMF to afford the diester 146 (yield: 43%). The diester
146 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise 1N HCl at 0 °C (till
pH 3-4) to afford the final compound 8 (yield: 61%).63
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Scheme 21. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 8.
Reagents and conditions. (a) CuI, PdCl2, PPh3, Et3N, CH3CN, 139, microwave, 100 °C, 15 min
(26%) or, 30min (63%) or, 60min (78%); (b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 85%; (c) DessMartin Periodinane, CH2Cl2, 0 °C to rt, 3 h, 84%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (e) 2,6diaminopyrimidin-4(3H)-one, CH3COONa, MeOH, 45 °C, 12 h, 46% over two steps; (f) 1N
NaOH, rt, 3 h; (ii). 1N HCl, 96%; (g) N-Methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5triazine, L-glutamate diethyl ester hydrochloride, DMF, rt, 12h, 43%; (h) (i). 1N NaOH, rt, 3 h;
(ii). 1N HCl, 61%.
5.

The synthesis of (S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-

yl)pentyl)furan-2-carbonyl)-L-glutamic acid 9.
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Scheme 22. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 9.
Reagents and conditions: (a) CuI, PdCl2, PPh3, Et3N, CH3CN, 147, microwave, 100 °C, 1 h, 57%;
(b) 10% Pd/C, H2, 55 psi, MeOH, 12 h, 74%; (c) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3
h, 71%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 4 h; (e) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa,
MeOH, 45 °C, 12 h, 23% over two steps; (f) 1N NaOH, rt, 3 h; (ii). 1N HCl, 92%; (g) NMethylmorpholine,

2-chloro-4,6-dimethoxy-1,3,5-triazine,

L-glutamate

diethyl

ester

hydrochloride, DMF, rt, 12 h, 98%; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 67%.
The scheme for the synthesis of compound 8 was followed for the target compound 9
(Scheme 22). In the first step of Scheme 21, as described above, the 60 min Sonogashira reaction
provided best yield among the three options. Thus, this 60 min Sonogashira coupling was
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performed with the unsaturated alcohol 147 and the bromofuroate 133 to afford 148 (yield: 57%).
Hydrogenation of 148 with 55 psi H2 in presence of catalyst palladium on carbon, provided the
saturated alcohol 149 (yield: 74%) which was then oxidized with Dess-Martin Periodinane to
obtain aldehyde 150 (yield: 71%). The aldehyde 150 was brominated to yield the α-bromoaldehyde
151, which was immediately used in the next step to condense with 2,6-diamino-4-oxo-pyrimidine
at 45 °C to afford the 5-substituted pyrrolo[2,3-d]pyrimidine 152 (yield 23% over two steps).
Compound 152 was hydrolyzed with 1N NaOH at room temperature to afford the acid 153 (yield:
92%). Similar to Scheme 21, glutamate coupling was performed in step 7 of Scheme 22 to keep
the molecular weight of the intermediates and as such, the loss in each purification step low. The
5-substituted pyrrolo[2,3-d]pyrimidine 153 was activated as described in Scheme 21 and was
coupled with L-glutamate diethyl ester hydrochloride in DMF to afford the diester 154 (yield:
98%). The diester 154 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise
1N HCl at 0 °C (till pH 3-4) to afford the final compound 9 (yield: 67%).63

6.

The synthesis of (S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-

yl)ethyl)-2-fluorobenzoyl)-L-glutamic acid 10.
The scheme pursued for compound 8 and 9 (Scheme 21 and Scheme 22 respectively)
provided relatively consistent yields in the critical Sonogashira coupling step (yield above 50% in
both the schemes) and hence the scheme was adopted to synthesize target compound 10 (Scheme
23). In the first step, a 60 minute Sonogashira coupling was performed between the
bromofluorobenzoate 155 and the unsaturated alcohol 156 to afford 157 (yield: 63%).
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Scheme 23. Synthesis of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidine 10.
Reagents and conditions(a) CuI, PdCl2, PPh3, Et3N, CH3CN, 156, microwave, 100 °C, 1 h, 63%;
(b) 10% Pd/C, H2, 55 psi, MeOH, 9 h, 94%; (c) Dess-Martin Periodinane, CH2Cl2, 0 °C to rt, 3 h,
44%, (d) Br2, 1,4-dioxane, CH2Cl2, rt, 3 h; (e) 2,6-diaminopyrimidin-4(3H)-one, CH3COONa,
MeOH, 45 °C, 12 h, 45% over two steps; (f) 1N NaOH, rt, 3 h; (ii). 1N HCl, 95%; (g) NMethylmorpholine,

2-chloro-4,6-dimethoxy-1,3,5-triazine,

L-glutamate

hydrochloride, DMF, rt, 12h, 58%; (h) (i). 1N NaOH, rt, 3 h; (ii). 1N HCl, 55%.
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diethyl

ester

Hydrogenation of 157 with catalyst palladium on carbon and 55 psi H2 provided the
saturated alcohol 158 (yield: 94%) which was then oxidized with Dess-Martin Periodinane to
obtain aldehyde 159 (yield: 44%). The aldehyde 159 was brominated to yield the α-bromoaldehyde
160, which was immediately used in the next step to condense with 2,6-diamino-4-oxo-pyrimidine
at 45 °C to afford the 5-substituted pyrrolo[2,3-d]pyrimidine 161 (yield: 45% over two steps).
Compound 161 was hydrolyzed with 1N NaOH at room temperature to afford the acid 162 (yield:
95%). Then 162 was activated with N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine and
coupled with L-glutamate diethyl ester hydrochloride in DMF to afford the diester 163 (yield:
58%). The diester 163 was hydrolyzed with 1N NaOH and then precipitated by adding dropwise
1N HCl at 0 °C (till pH 3-4) to afford the final compound 10 (yield: 55%).63
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V. SUMMARY
In this study the design and synthesis of 5-substituted pyrrolo[2,3-d]pyrimidines as
potential selective antifolate has been described. A total of five final compounds and thirty seven
intermediates were synthesized as part of the study. Among the five final compounds, four were
novel (6-9) and one (10) was previously reported. The previously reported compound was
synthesized to explore previously unexplored FR/GARFTase selective biological activity. Four out
of five final compounds were submitted for biological evaluation.
Table 3: IC50s (in nM) for 5- substituted pyrrrolo[2,3-d]pyrimicline antifolates 6, 7, 8,
10 and classical antifolates in RFC-, PCFT-, and FR-expressing cell lines
Cmpd.

Structure

6

5-pyrrole/4C/
1,2-phenyl
5-pyrrole/3C/
2,5-furan
5-pyrrole/4C/
2,5-furan
5-pyrrole/2C/
fluorophenyl
5-pyrrole/2C/
1,4-phenyl
-

7
8
10
PMX
(13)
MTX
RTX
LMTX

RFC
PC4310
>1000

FRα
RT16
>1000

>1000

>1000

>1000

862

>1000

607.9

>1000

959.7

>1000

196

>1000

>1000

709

169

6.8

26

8.9

73.4

22.3(8.6)

-

9.94(3.11)

120.5(16.8)
99.5(11.4)
38.0(5.3)

-

6.0(0.6)
5.9(2.2)
1.2(0.6)

30.6
18.2(3.8)
(6.2)
12(1.1) 114(31)
6.3(1.3)
15(5)
12(2.3)
12(8)

PCFT
FRβ
R2/hPCFT4 D4/FRβ

KB
KB

Among the evaluated compounds, 6 totally lacked KB cell line inhibitory activity (IC50 >
1000 nM). Compound 7, containing a 3C linker and a furan in the sidechain, had very little KB
cell inhibitory activity (IC50 = 959.7 nM) resulting from limited RFC and PCFT transport. The
compound demonstrated slight PCFT selectivity over RFC (PCFT IC50 = 607.9 nM and RFC IC50
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= 862 nM). Increasing the chain length from 3C to 4C (compound 8) resulted in a dramatic change
by totally eliminating the PCFT and RFC activity. However, 8 gained FRα (IC50 = 196 nM)
selectivity over RFC (IC50 > 1000 nM). Replacement of sidechain furan with a fluorophenyl
provided 10 which closely mimicked PMX; except for the presence of an extra fluorine atom on
the sidechain aromatic group. Compared to other target compounds, 10 demonstrated better KB
cell inhibition (IC50 = 73 nM) and good FRα and PCFT activity, but the FRα and PCFT selectivity
over RFC was reduced (RFC IC50 = 169 nM, FRα IC50 = 6.8 nM and PCFT IC50 = 26 nM)
compared to 8. However, 10 still demonstrated better FRα and PCFT selectivity over RFC than
PMX (RFC IC50 = 30.6 nM, FRα IC50 = 18.2 nM and PCFT IC50 = 22.3 nM).
The target compounds synthesized as part of this study are as follows:
1. (S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)benzoyl)-L-glutamic acid (6)
2. (S)-diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)propyl)furan-2-carbonyl)-L-glutamic acid (7)
3. (S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)furan-2-carbonyl)-L-glutamic acid (8).
4. (S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)pentyl)furan-2-carbonyl)-L-glutamic acid (9)
5. (S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl)-2-fluorobenzoyl)-L-glutamic acid (10).
Major intermediates synthesized as part of this study are as follows:
1. 2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-557

yl)butyl)benzoic acid (125)
2. (S)-diethyl (2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)benzoyl)-L-glutamate (126)
3. (S)-diethyl (5-(4-bromo-5-oxopentyl)furan-2-carbonyl)-L-glutamate (131).
4. (S)-diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)propyl)furan-2-carbonyl)-L-glutamate (132)
5.

(S)-diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)furan-2-carbonyl)-L-glutamate (146)

6. 5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)pentyl)furan-2-carboxylic acid (153)
7. (S)-diethyl (5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)pentyl)furan-2-carbonyl)-L-glutamate (154)
8.

(S)-diethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl)-2-fluorobenzoyl)-L-glutamate (163)
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VI. EXPERIMENTAL
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples
were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P2O5 at 60 °C. Melting
points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic
thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (1H NMR) were
recorded on Bruker Avance II 400 (400 MHz) and 500 (500 MHz) spectrometer. The chemical
shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal
standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Thin-layer
chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a
fluorescent indicator, and the spots were visualized under 254 and 366 nm illumination.
Proportions of solvents used for TLC are by volume. Column chromatography was performed on
CombiFlash Rf system (Teledyne ISCO, NE) with commercially available CombiFlash compatible
12g, 24g or 40g silica columns (Teledyne ISCO, NE). The compounds were dry-packed on
cartridge to use in the CombiFlash system. Packing was performed with either silica gel or celite
of at least three times the weight of the crude. Elemental analyses were performed by Atlantic
Microlab, Inc., Norcross, GA. Element compositions are determined with either one of the
following softwares: Seareg (within ±0.4% of the calculated values), JASPER (not within ±0.4%
of the calculated values). Fractional moles of water or organic solvents frequently found in some
analytical samples of antifolates could not be prevented despite 24-48 h of drying in vacuo and
were confirmed where possible by their presence in the 1H NMR spectra. All solvents and
chemicals were purchased from Aldrich Chemical Co., Fisher Scientific and Matrix Scientific and
were used as received.

59

Ethyl 2-(6-oxohexyl)benzoate (122). The alcohol hex-5-en-1-ol 120 (10.87 mmol, 1.09 g) was
added to a solution of ethyl 2-iodobenzoate (121) (9.06 mmol, 2.5 g) in 30 mL of anhydrous DMF.
Then LiCl (9.06 mmol, 383.90 mg), LiOAc (22.64 mmol, 1.49 g), Bu4NCl (4.53 mmol, 1.26 g),
and Pd(OAc)2 (543.34 mmol, 121.98 mg) was also added to the mixture, and the mixture was
stirred at 70 °C for 4 h. TLC (hexane/EtOAc, 3:1) showed the disappearance of the starting material
(Rf = 0.90) and formation of one major spot at Rf = 0.81. To the reaction mixture cooled to room
temperature was add ethyl acetate (30 mL). The resulting solution was extracted with H2O (10 mL
× 3) and dried over Na2SO4. After evaporation of solvent, the residue was loaded on a silica gel
column (4 × 20 cm) and flash chromatographed with hexane/EtOAc, and the desired fractions (at
3% EtOAc) were pooled. After evaporation of the solvent, the residue was dried in vacuo using
P2O5 to afford 122 (1.54 g, yield 68%) as a colorless liquid, which was used directly for the next
step without characterization. TLC Rf 0.81 (hexane/EtOAc 3:1).
Ethyl 2-(5-bromo-6-oxohexyl)benzoate (123). To 0.928 ml (10.85 mmol) dioxane, Br2 (0.317
ml, 6.2 mmol) was added dropwise and the mixture was stirred for 10 min, and diluted with CH2Cl2
(3.09 ml, 48.37 mmol). This solution was added dropwise to an ice-cool solution of 122 (1.54 g,
6.20 mmol) in CH2Cl2 (3.09 ml, 48.37 mmol) over 3 h under N2. The mixture was stirred for 0.5
h, then a solution of Na2CO3 in water (15 ml) was added. After being stirred for 1h, the reaction
mixture was extracted with CHCl3 (15 ml). TLC was run and a new non polar spot was identified.
The compound was unstable, so, it was immediately used for the cyclization reaction without
characterization.
Ethyl

2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoate

(124). To a solution of 2,6-diamino-4-oxopyrimidine (860.66 mg, 6.82 mmol) and sodium acetate
(1.02 g, 12.41 mmol) in water (15 mL) and methanol (15 mL) was added α-bromo aldehyde 123
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(2.03 mg, 6.20 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the
disappearance of starting materials and the formation of one major spot at Rf = 0.72
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by
silica gel (4 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel
column (3.5 cm ×15 cm) and eluted by combiflash. Fractions showing Rf = 0.72 (CHCl3/MeOH,
5:1) were pooled and evaporated to afford 124 (1.12 g, yield 51% over two steps). TLC Rf 0.72
(CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 10.56 (s, 1H), 10.05 (s, 1H), 7.71-7.73
(dd, J = 1.4, 7.8 Hz, 1H), 7.44-7.48 (td, J = 1.4, 7.7 Hz, 1H), 7.32-7.27 (m, 2H), 6.31-6.32 (d, J =
2.1 Hz, 1H), 5.92 (s, 2H), 4.24-4.30 (q, J = 7.1 Hz, 2H), 2.83-2.92 (m, 2H), 2.56-2.60 (t, J = 7.4
Hz, 2H), 1.51-1.65 (dq, J = 7.8, 35.9 Hz, 4H), 1.27-1.31 (t, J = 7.1 Hz, 3H).
2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoic acid (125).
To 124 (1.12 g, 3.16 mmol) in 30 mL of CH3OH was added 1 N NaOH (30 mL). The resulting
mixture was stirred at 45 °C for 14 h. TLC indicated the disappearance of starting material and the
formation of one major spot at Rf = 0.63 (CHCl3/MeOH 5:1). To this was added distilled water
(10 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl.
The resulting suspension was chilled and thawed to 4 °C overnight in a refrigerator. The precipitate
was filtered, washed with cold water, and dried in a desiccator under reduced pressure using P2O5
(795 mg, 2.44 mmol) to afford 125 (0.79 g, yield 77%). Pale blue powder; MP > 180 °C
(decomposed); TLC Rf = 0.63 (CHCl3/MeOH 5:1); 1H NMR (DMSO-d6):  12.81 (s, 1H), 10.63
(s, 1H), 10.16 (s, 1H), 7.73-7.75 (dd, 1H), 7.42-7.45 (td, 1H), 7.25-7.29 (m, 2H), 6.34-6.35 (d,
1H), 6.02 (s, 2H), 2.89-2.93 (m, 2H), 2.55-2.58 (t, 2H), 1.53-1.61 (dq, 4H). Anal. calculated for
(C17H18N4O3 · 0.8 H2O): C, 59.93; H, 5.79; N, 16.44; Found: C, 60.01; H, 5.60; N, 16.09.
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(S)-diethyl(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)benzoyl)-L-glutamate (126). To a solution of 125, (500 mg, 1.53 mmol) in anhydrous
DMF (20 mL) was added N-methylmopholine (0.2 mL, 1.8 mmol) and 2-chloro-4,6-dimethoxy1,3,5-triazine (322 mg, 1.8 mmol). The resulting mixture was stirred at room temperature for 2 h.
To this mixture was added N-methylmopholine (0.2 mL, 1.8 mmol) and L-glutamic acid diethyl
ester hydrochloride (473 mg, 2.3 mmol). The reaction mixture was stirred for an additional 4 h at
room temperature and then evaporated to dryness under reduced pressure. The residue was mixed
with 1 g of silica gel to make a plug and chromatographed with combiflash with 10% MeOH in
CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were pooled and evaporated to
dryness to afford 126 (769 mg, yield 98%). TLC Rf 0.84 (CHCl3/MeOH 5:1); compound was not
characterized and was carried on to the next step.
(S)-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoyl)-Lglutamic acid (6). To a solution of the 126 (769 mg, 1.5 mmol) in MeOH (10 mL) was added 1N
NaOH (10 mL) and the mixture was stirred at room temperature for 4 h. Then distilled water (5
mL) was added, and the pH was adjusted to 3-4 by dropwise addition of 1N HCl. The resulting
suspension was chilled and thawed to 4 °C overnight in a refrigerator. The precipitate was filtered,
washed with water and dried under vacuum with P2O5 to afford 6 (310 mg, yield 46%) as a dark
blue powder. MP > 210 °C (decomposed); 1H NMR (DMSO-d6): δ 12.42 (s, 2H), δ 10.61-10.62
(d, 1H), 10.14 (s, 1H), 8.54-8.56 (d, 1H), 7.29-7.35 (m, 2H), 7.21-7.27 (m, 2H), 6.25-6.40 (d, 1H),
5.97 (s, 2H), 4.34-4.40 (ddd, 1H), 2.69-2.74 (m, 1H), 2.54-2.57 (t, 2H), 2.36-2.40 (m, 2H), 1.822.11 (m, 2H), 1.52-1.57 (m, 4H). Anal. calculated for (C22H25N5O6 · 0.65 H2O): C, 56.56; H, 5.67;
N, 14.99; Found: C, 56.07; H, 5.53; N, 15.55.
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(S)-diethyl (5-bromofuran-2-carbonyl)-L-glutamate (128): To do the peptide coupling, acid
127 (1 gm, 5.24 mmol) was taken in 50 mL DMF then 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.1
gm, 6.28 mmol) and N-methylmorpholine (635.55 mg, 6.28 mmol) were added. This was stirred
in room temperature for 2 h. Then L-glutamate diethyl ester hydrochloride (1.62 gm, 7.96 mmol)
and N-methylmorpholine (635.55 mg, 6.28 mmol) was added. This was stirred at room temperature
for 12 hrs. TLC showed complete use of the starting material and formation of a major new spot
at Rf = 0.58 (Hexane/EtOAc, 1:1). The reaction mixture was evaporated to dryness under reduced
pressure. The residue was dissolved in MeOH, celite added and solvent evaporated to make a plug.
From column run in combiflash, factions that showed the desired single spot at R f = 0.58 were
pooled and evaporated to dryness to afford 128 (1.75 gm, yield 89 %). TLC Rf 0.58
(Hexane/EtOAc, 1:1); Viscous colorless liquid; 1H NMR (DMSO-d6): δ 8.73-8.75 (d, J = 7.7 Hz,
1H), 7.22-7.23 (d, J = 3.5 Hz, 1H), 6.78-6.79 (d, J = 3.5 Hz, 1H), 4.38-4.44 (ddd, J = 5.1, 7.6, 9.7
Hz, 1H), 4.09-4.15 (qd, J = 1.4, 7.0 Hz, 2H), 4.02-4.07 (q, J = 7.1 Hz, 2H), 2.39-2.43 (t, J = 7.5
Hz, 2H), 1.93-2.15 (m, 2H), 1.15-1.21 (dt, J = 7.1, 8.4 Hz, 6H).
(S)-diethyl (5-(5-oxopentyl)furan-2-carbonyl)-L-glutamate (130): To a solution of 128 (3.85
mmol, 1.45 mg) in 30 mL of anhydrous DMF were added pent-4-en-1-ol 129 (4.46 mmol, 400
mg), LiCl (3.85 mmol, 163 mg), LiOAc (9.66 mmol, 637 mg), Bu4NCl (1.95 mmol, 542 mg), and
Pd(OAc)2 (0.232 mmol, 52 mg), and the mixture was stirred at 70 °C for 4 h. TLC showed the
disappearance of the starting material and formation of one major spot at Rf = 0.2 (hexane/EtOAc,
1:1). To the reaction mixture, cooled to room temperature, was add ethyl acetate (30 mL). The
resulting solution was extracted with H2O (10 mL × 3) and dried over Na2SO4. After evaporation
of solvent, the residue was loaded on a silica gel column (4 × 20 cm) and flash chromatographed
with hexane/EtOAc system, and the desired fractions (at 38% EtOAc) were pooled. After
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evaporation of the solvent, the residue was dried in vacuo using P2O5 to afford 130 (672 mg, yield
38%) as a light yellow liquid. TLC Rf 0.2 (hexane/EtOAc, 1:1); Light yellow liquid; 1H NMR
(400 MHz, Chloroform-d): δ 9.805-9.817 (t, J = 1.5 Hz, 1H), 7.05-7.06 (dd, J = 1.8, 3.4 Hz, 1H),
6.92-6.94 (d, J = 8.1 Hz, 1H), 6.15-6.16 (d, J = 3.4 Hz, 1H), 4.77-4.82 (td, J = 5.0, 8.1 Hz, 1H),
4.23-4.29 (qd, J = 2.7, 7.2 Hz, 2H), 4.08-4.18 (m, 2H), 2.68-2.77 (m, 2H), 2.37-2.66 (m, 4H), 2.042.38 (m, 2H), 1.73-1.76 (q, J = 3.4 Hz, 4H), 1.31-1.35 (t, J = 7.1 Hz, 3H), 1.23-1.27 (t, J = 7.2 Hz,
3H).
(S)-diethyl (5-(5-oxopentyl)furan-2-carbonyl)-L-glutamate (130); Alternative scheme:
Compound 138 (824 mg, 2.15 mmol) in anhydrous CH2Cl2 (5 mL) was added to a stirred solution
of Dess-Martin periodinane (1.1 g, 2.59 mmol) in CH2Cl2 (5 mL) at 0 °C, and then the mixture was
allowed to warm to room temperature. Stirring was continued for 3 h. When the reaction was
complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were
washed with brine, dried with MgS04, and concentrated to afford 130 (610 mg, yield 74%) as light
yellow liquid. 1H NMR (400 MHz, Chloroform-d): δ 9.80-9.81 (t, J = 1.5 Hz, 1H), 7.05-7.06 (dd,
J = 1.8, 3.4 Hz, 1H), 6.92-6.94 (d, J = 8.1 Hz, 1H), 6.15-6.16 (d, J = 3.4 Hz, 1H), 4.77-4.82 (td, J
= 5.0, 8.1 Hz, 1H), 4.23-4.29 (qd, J = 2.7, 7.2 Hz, 2H), 4.08-4.18 (m, 2H), 2.68-2.77 (m, 2H), 2.372.66 (m, 4H), 2.04-2.38 (m, 2H), 1.73-1.76 (q, J = 3.4 Hz, 4H), 1.31-1.35 (t, J = 7.1 Hz, 3H), 1.231.27 (t, J = 7.2 Hz, 3H).
(S)-diethyl (5-(4-bromo-5-oxopentyl)furan-2-carbonyl)-L-glutamate (131). To 1,4-dioxane
(271 mg, 3.08 mmol) dissolved in CH2Cl2 (3 ml), Br2 (281 mg, 1.76 mmol) was added dropwise
and the mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added
64

dropwise to an ice-cool solution of 130 (672 mg, 1.76 mmol) in CH2Cl2 (3 ml) over 3 h under N2.
The mixture was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After
being stirred for 1h, the reaction mixture was extracted with CHCl3 (10 ml). TLC was run and a
new non polar spot was identified. The compound was unstable, so, it was immediately used for
the next step.
(S)-diethyl(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan2-carbonyl)-L-glutamate (132). To a solution of 2,6-diamino-4-oxopyrimidine (244 mg, 1.94
mmol) and sodium acetate (289 mg, 3.52 mmol) in water (10 mL) and methanol (10 mL) was
added α-bromo aldehyde 131 (1.76 mmol) The reaction mixture was stirred at 45 °C for 12 h. TLC
showed the disappearance of starting materials and the formation of one major spot at Rf = 0.48
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by
silica gel (4 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel
column and eluted by combiflash. Fractions showing Rf = 0.48 were pooled and evaporated to
afford 132 (99 mg, yield 12% over two steps) as a dark brown powder. MP 83 °C; TLC Rf 0.48
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6): δ 10.68 (s, 1H), 10.12 (s, 1H), 8.47-8.49 (d, J = 7.7
Hz, 1H), 7.07-7.08 (d, J = 3.3 Hz, 1H), 6.39-6.40 (d, J = 2.1 Hz, 1H), 6.33-6.44 (d, J = 3.4 Hz,
1H), 6.00 (s, 2H), 4.36-4.42 (q, J = 7.8 Hz, 1H), 4.08-4.14 (m, 2H), 4.01-4.06 (q, J = 7.1 Hz, 2H),
2.61-2.68 (dt, J = 7.4, 15.5 Hz, 4H), 2.38-2.41 (t, J = 7.4 Hz, 2H), 1.94-2.14 (m, 4H), 1.18-1.20
(m, 3H), 1.14-1.17 (m, 3H). Anal. calculated for (C23H29N5O7 · 0.29 CHCl3): C, 53.52; H, 5.64;
N, 13.39; Found: C, 53.58; H, 5.71; N, 13.21.
(S)-diethyl(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)furan2-carbonyl)-L-glutamate (7). To 132 (99 mg, 203 mmol) in 10 mL of CH3OH was added 1 N
NaOH (5 mL). The resulting mixture was stirred at room temperature for 2 hrs. TLC indicated the
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disappearance of starting material and the formation of one major spot at Rf = 0.4 (CHCl3/MeOH,
5:1 with 1 drop glacial acetic acid). To this was added distilled water (5 mL). The solution was
cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The resulting suspension was
thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, washed with cold water,
and dried in a desiccator under reduced pressure using P2O5 to afford 7 (39 mg, yield 45%).
Brownish white powder. MP > 153 °C (decomposed); TLC Rf 0.4 (CHCl3/MeOH, 5:1 in acidic
condition); 1H NMR (DMSO-d6): δ 12.31 (s, 1H), 10.68 (s, 1H), 10.12 (s, 1H), 8.34-8.36 (d, J =
7.9 Hz, 1H), 7.06-7.08 (d, J = 3.3 Hz, 1H), 6.40-6.42 (d, J = 2.1 Hz, 1H), 6.31-6.33 (d, J =3.4 Hz,
1H), 6.00 (s, 2H), 4.31-4.38 (d, J = 9.9 Hz, 1H), 2.61-2.68 (dt, J = 7.5, 14.8 Hz, 4H), 2.30-2.34 (t,
J = 7.6 Hz, 2H), 1.94-2.07 (dd, J = 8.2, 45.0 Hz, 4H). Anal. calculated for (C19H21N5O7 · 1 H2O):
C, 50.75; H, 5.16; N, 15.57; Found: C, 50.76; H, 4.89; N, 15.46.
Methyl 5-(5-hydroxypent-1-yn-1-yl)furan-2-carboxylate (135): To a 20-mL vial for microwave
reaction, was added a mixture of palladium chloride (276.57 mg, 1.56 mmol), triphenylphosphine
(409.10 mg, 1.56 mmol), triethylamine (400.19 mg, 9.75 mmol), methyl 5-bromofuran-2carboxylate, 133 (2 g, 9.75 mmol) and anhydrous acetonitrile (10 mL). To the stirred mixture, were
added copper(I) iodide (297.05 mg, 1.56 mmol), and pent-4-yn-1-ol, 134 (820 mg, 9.75 mmol),
and the vial was sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new
spot between the two starting material. This reaction was repeated three times with same outcome,
reaction mixtures were mixed and solvent evaporated. Then methanol and celite (10 g) was added
and the solvent was evaporated under reduced pressure. The resulting plug was subjected flash
chromatographed using combiflash machine in EtOAc/hexane system. The desired fraction (TLC)
was collected and the solvent was evaporated under reduced pressure to afford 3.57 g (yield 58%)
of 135 as orange brown powder. MP 53 °C; TLC Rf 0.45 (hexane/EtOAc 1:1); 1H NMR (400 MHz,
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Chloroform-d):  7.15-7.16 (d, J = 3.5 Hz, 1H), 6.55-6.56 (d, J = 3.6 Hz, 1H), 3.92 (s, 3H), 3.803.84 (q, J = 5.8 Hz, 2H), 2.59-2.62 (t, J = 7.0 Hz, 2H), 1.85-1.92 (m, 2H), 1.44-1.46 (t, J = 5.1 Hz,
1H). Anal. calculated for (C11H12O4 · 0.17 H2O): C, 62.53; H, 5.88; Found: C, 62.52; H, 5.75.
Methyl 5-(5-hydroxypentyl)furan-2-carboxylate (136): To a Parr flask was added 135 (1.5 g,
7.2 mmol), 10% palladium on activated carbon (1.5 g), and MeOH (100 mL). Hydrogenation was
carried out at 55 psi of H2 for 12 h. The reaction mixture was filtered through Celite, washed with
MeOH (100 mL) and concentrated under reduced pressure to give 1.1 g (72%) of 136 as pale
yellow semisolid. TLC Rf 0.48 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.117.12 (d, J = 3.4 Hz, 1H), 6.14-6.15 (m, 1H), 3.89 (s, 3H), 3.65-3.68 (t, J = 6.5 Hz, 2H), 2.71-2.75
(t, J = 7.5 Hz, 2H), 1.72-1.78 (m, 2H), 1.58-1.65(ddt, J = 6.2, 8.4, 9.8 Hz, 2H), 1.40-1.48 (m, 3H).
5-(5-hydroxypentyl)furan-2-carboxylic acid (137). To 136 (1.1 g, 5.18 mmol) was added 1 N
NaOH (5 mL). The resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the
disappearance of starting material and the formation of one major spot at Rf = 0.4 (CHCl3/MeOH,
5:1). To this was added distilled water (5 mL). The solution was cooled in an ice bath, and the pH
was adjusted 3 to 4 using 1 N HCl. The resulting suspension was thawed to 4 °C overnight in a
refrigerator. The precipitate was filtered, washed with cold water, and dried in a desiccator under
reduced pressure using P2O5 to afford 137 (484 mg, yield 47%). White powder. MP 55 °C; TLC
Rf 0.4 (CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6): δ 7.25-7.26 (d, J = 3.5 Hz, 1H), 6.20-6.21 (d,
J = 3.5 Hz, 1H), 3.67-3.70 (t, J = 6.5Hz, 2H), 2.74-2.78 (t, J = 7.6 Hz, 2H), 1.72-1.80 (m, 2H),
1.60-1.67 (dq, J = 6.7, 8.7 Hz, 2H), 1.42-1.50 (m, 2H). Anal. calculated for (C10H14O4): C, 60.59;
H, 7.11; Found: C, 60.50; H, 7.03.
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(S)-diethyl (5-(5-hydroxypentyl)furan-2-carbonyl)-L-glutamate (138): In 50 mL DMF 137
(475 mg, 2.40 mmol) was added. Then 2-chloro-4,6-dimethoxy-1,3,5-triazine (504.88 mg, 2.88
mmol), N-methylmorpholine (605.97 mg, 5.99 mmol) and L-glutamate diethyl ester hydrochloride
(730.54 mg, 3.59 mmol) were added in the stirred solution. This was stirred at room temperature
for 12 hrs. TLC showed formation of a major new spot at Rf = 0.22 (Hexane/EtOAc, 1:1). The
reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in
MeOH, celite added and solvent evaporated to make a plug. From column run in combiflash
(Hexane/EtOAc system), factions that showed the desired single spot at Rf = 0.22 were pooled
and evaporated to dryness to afford 138 (826 mg, yield 90%). Rf = 0.22 (Hexane/EtOAc, 1:1);
Colorless liquid; 1H NMR (400 MHz, Chloroform-d): δ 7.04-7.05 (d, J = 3.4 Hz, 1H), 6.95-6.97
(d, J = 8.0 Hz, 1H), 6.12-6.13 (m, 1H), 4.77-4.82 (td, J = 4.9, 8.2 Hz, 1H), 4.21-4.29 (qd, J = 2.5,
7.1 Hz, 2H), 4.09-4.15 (qd, J = 0.9, 7.1 Hz, 2H), 3.67-3.70 (t, J = 6.4 Hz, 2H), 2.69-2.73 (t, J = 7.5
Hz, 2H), 2.38-2.54 (m, 2H), 2.06-2.37 (m, 2H), 1.68-1.77 (p, J = 7.6 Hz, 2H), 1.60-1.67 (m, 2H),
1.44-1.52 (m, 2H), 1.30-1.34 (t, J = 7.1 Hz, 3H), 1.23-1.27 (t, J = 7.1 Hz, 3H).
Methyl 5-(6-hydroxyhex-1-yn-1-yl)furan-2-carboxylate (140): To a 20-mL vial for microwave
reaction, was added a mixture of palladium chloride (202.35 mg, 1.14 mmol), triphenylphosphine
(299.32 mg, 1.14 mmol), triethylamine (7.22 g, 71.32 mmol), methyl 5-bromofuran-2-carboxylate,
133 (1.46 g, 7.13 mmol) and anhydrous acetonitrile (8 mL). To the stirred mixture, were added
copper(I) iodide (217.34 mg, 1.14 mmol), and hex-5-yn-1-ol, 139 (700 mg, 7.13 mmol), and the
vial was sealed and put into the microwave reactor at 100 °C for 15 min. TLC showed a new spot
with Rf = 0.63 (hexane/EtOAc 1:1) between the two starting material. This reaction was repeated
two more times for 30 min and 1 h respectively. For each reaction mixture solvent (acetonitrile)
was evaporated. Then methanol and celite (4 g) was added and the solvent was evaporated under
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reduced pressure. The resulting plug was subjected to flash chromatography using combiflash
machine in EtOAc/hexane system. The desired fraction (TLC) was collected and the solvent was
evaporated under reduced pressure to afford 140 as dark brown semisolid. Yield for 15 min, 30
min, 1 h reactions were 26% (425 mg), 63% (1 g) and 79% (1.25 g) respectively. Dark brown
semisolid; TLC Rf 0.63 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.15-7.16 (d,
J = 3.5 Hz, 1H), 6.54-6.55 (d, J = 3.5 Hz, 1H), 3.91 (s, 3H), 3.71-3.74 (m, 2H), 2.50-2.53 (t, J =
6.6 Hz, 1H), 1.68-1.79 (tdd, J = 2.6, 4.3, 7.1 Hz, 4H), 1.35 (s, 1H).
Methyl 5-(6-hydroxyhexyl)furan-2-carboxylate (141): To a Parr flask was added 140 (2.67 g,
11.70 mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was
carried out at 55 psi of H2 for 12 h. The reaction mixture was filtered through Celite, washed with
MeOH (100 mL) and concentrated under reduced pressure to give 2.45 g (90%) of 141. Light
brown liquid; TLC Rf 0.60 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.12-7.13
(d, J = 3.3 Hz, 1H), 6.14-6.15 (m, 1H), 3.89-3.90 (d, J = 1.6 Hz, 3H), 3.64-3.68 (td, J = 1.3, 6.5
Hz, 2H), 2.70-2.74 (t, J = 7.6 Hz, 2H), 1.68-1.76 (m, 2H), 1.59-1.61 (m, 2H), 1.38-1.43 (p, J = 3.6
Hz, 4H).
Methyl 5-(6-oxohexyl)furan-2-carboxylate (142): To a stirred solution of Dess-Martin
periodinane (5.4 g, 12.73 mmol) in CH2Cl2 (8 mL), methyl 5-(6-hydroxyhexyl)furan-2carboxylate, 141 (2.4 g, 10.61 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was
continued for 3 h and the mixture was allowed to warm to room temperature. When the reaction
was complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were
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washed with brine, dried with MgS04, and concentrated to afford 142 (2 g, yield 84%). Pale yellow
liquid. 1H NMR (400 MHz, Chloroform-d): δ 9.78-9.79 (t, J = 1.4 Hz, 1H), 7.11-7.13 (d, J = 3.4
Hz, 1H), 6.14-6.15 (dd, J = 0.9, 3.3 Hz, 1H), 3.89-3.90 (d, J = 0.9 Hz, 3H), 2.70-2.74 (t, J = 7.6
Hz, 2H), 2.45-2.49 (tt, J = 1.1, 7.4 Hz, 2H), 1.64-1.77 (dp, J = 7.5, 19.1 Hz, 4H), 1.37-1.44 (m,
2H).
Methyl 5-(5-bromo-6-oxohexyl)furan-2-carboxylate (143). To 1,4-dioxane (1.38 g, 15.61
mmol) dissolved in CH2Cl2 (5 ml), Br2 (1.43 g, 456.8 mmol) was added dropwise and the mixture
was stirred for 10 min, and diluted with CH2Cl2 (5 ml). This solution was added dropwise to an
ice-cool solution of 142 (2 g, 8.92 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The mixture was
stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being stirred for 1h,
the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new non polar spot
was identified. The compound, 143, was unstable, so, it was immediately used for the next step.
Methyl

5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2-

carboxylate (144). To a solution of 2,6-diamino-4-oxopyrimidine (1.24 g, 9.8 mmol) and sodium
acetate (4.46 g, 17.81 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo aldehyde
143 (8.91 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the
disappearance of starting materials and the formation of one major spot at Rf = 0.56
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by
silica gel (10 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel
column and eluted by combiflash. Fractions showing Rf = 0.56 were pooled and evaporated to
afford 144 (1.43 g, yield 48% over two steps) as a dark brown powder. MP 149 °C; TLC Rf 0.56
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6): δ 10.63 (s, 1H), 10.1 (s, 1H), 7.20-7.21 (d, 1H), 6.34-
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6.35 (d, 2H), 5.97 (s, 2H), 3.78 (s, 3H), 2.56-2.70 (m, 4H), 1.61-1.63 (m, 4H). Anal. calculated for
(C16H18N4O4 · 1.65 CH3OH): C, 55.32; H, 6.47; N, 14.62; Found: C, 55.87; H, 5.69; N, 13.85.
5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2-carboxylic
acid (145). To 144 (1 g, 3.03 mmol) was added 1 N NaOH (4 mL). The resulting mixture was
stirred at room temperature for 3 hrs. TLC indicated the disappearance of starting material and the
formation of one major spot at Rf = 0.23 (CHCl3/MeOH, 5:1). To this was added distilled water
(4 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered,
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 145
(920 mg, yield 96%). Black semisolid; TLC Rf 0.23 (CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6):
δ 10.62-10.63 (d, J = 2.2 Hz, 1H), 10.18 (s, 1H), 7.02-7.03 (d, J = 3.4 Hz, 1H), 6.34-6.35 (d, J =
2.0 Hz, 1H), 6.25-6.26 (d, J = 3.4 Hz, 1H), 6.01 (s, 2H), 2.57-2.67 (dt, J = 7.1, 29.1 Hz, 4H), 1.611.63 (m, 4H).
(S)-diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan2-carbonyl)-L-glutamate (146): In 50 mL DMF, 145 (505 mg, 1.60 mmol) was added. Then 2chloro-4,6-dimethoxy-1,3,5-triazine (336.36 mg, 1.92 mmol), N-methylmorpholine (403.71 mg,
3.99 mmol) and L-glutamate diethyl ester hydrochloride (493.19 mg, 2.43 mmol) were added in
the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a
major new spot at Rf = 0.59 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired
single spot at Rf = 0.59 were pooled and evaporated to dryness to afford 146 (344 mg, yield 43%).
Brown powder; MP > 143 °C (decomposed); TLC Rf 0.59 (CHCl3/MeOH, 5:1); 1H NMR (400
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MHz, DMSO-d6): δ 10.63 (s, 1H), 10.11 (s, 1H), 8.47-8.49 (d, J = 7.6 Hz, 1H), 7.06-7.07 (d, J =
3.3 Hz, 1H), 6.34-6.35 (d, J = 2.0 Hz, 1H), 6.26-6.27 (d, J = 3.4 Hz, 1H), 5.97 (s, 2H), 4.36-4.42
(m, 1H), 4.09-4.13 (qd, J = 1.5, 7.2 Hz, 2H), 4.02-4.08 (q, J = 7.1 Hz, 2H), 2.58-2.67 (d, J = 32.1
Hz, 4H), 2.38-2.42 (t, J = 7.5 Hz, 2H), 2.06-2.12 (p, J = 6.7, 7.4 Hz, 1H), 1.93-2.03 (m, 2H), 1.641.66 (m, 4H), 1.15-1.20 (dt, J = 7.1, 9.0 Hz, 6H). Anal. calculated for (C24H31N5O7 · 1.25 H2O):
C, 55.01; H, 6.44; N, 13.36; Found: C, 52.29; H, 5.82; N, 16.11.
(S)-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)furan-2carbonyl)-L-glutamic acid (8). To 146 (100 mg, 0.199 mmol) was added 1 N NaOH (2 mL). The
resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the disappearance of
starting material and the formation of one very polar major spot. To this was added distilled water
(2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered,
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 8
(54 mg, yield 61%). Light green powder; TLC Rf 0.2 (CHCl3/MeOH, 5:1 in acidic condition); 1H
NMR (DMSO-d6): δ 10.63 (s, 1H), 10.12 (s, 1H), 8.35-8.37 (d, J = 7.9 Hz, 1H), 7.05-7.06 (d, J
= 3.4 Hz, 1H), 6.35-6.36 (d, J = 2.1 Hz, 1H), 6.26-6.27 (d, J = 3.3 Hz, 1H), 5.98 (s, 2H), 4.32-4.38
(m, 1H), 2.65-2.70 (d, J = 4.5 Hz, 2H), 2.60 (s, 2H), 2.30-2.34 (t, J = 7.5 Hz, 2H), 1.87-2.10 (m,
2H), 1.61-1.68 (m, 4H). Anal. calculated for (C20H23N5O7 · 0.88 H2O): C, 52.05; H, 5.41; N, 15.17;
Found: C, 52.09; H, 5.34; N, 15.04.
Methyl 5-(7-hydroxyhept-1-yn-1-yl)furan-2-carboxylate (148): To a 20-mL vial for microwave
reaction, was added a mixture of palladium chloride (278.22 mg, 1.57 mmol), triphenylphosphine
(411.54 mg, 1.57 mmol), triethylamine (9.92 g, 98.06 mmol), methyl 5-bromofuran-2-carboxylate,
133 (2 g, 9.8 mmol) and anhydrous acetonitrile (7 mL). To the stirred mixture, were added
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copper(I) iodide (298.82 mg, 1.57 mmol), and hept-6-yn-1-ol, 147 (1.1 g, 9.81 mmol), and the vial
was sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new spot with Rf
= 0.35 (hexane/EtOAc 1:1) between the two starting material. This reaction was repeated one
more time with similar outcome. Two reaction mixtures were mixed and solvent (acetonitrile) was
evaporated. Then methanol and celite (12 g) was added and the solvent was evaporated under
reduced pressure. The resulting plug was subjected to flash chromatography using combiflash
machine in EtOAc/hexane system. The desired fraction (TLC) was collected and the solvent was
evaporated under reduced pressure to afford 148 (3.99 g, yield 57%). Dark brown semisolid; TLC
Rf 0.35 (hexane/EtOAc 1:1); 1H NMR (400 MHz, DMSO-d6): δ 7.33-7.34 (d, J = 3.6 Hz, 1H),
6.86-6.87 (d, J = 3.7 Hz, 1H), 3.81 (s, 3H), 3.39-3.42 (t, J = 5.9 Hz, 2H), 1.52-1.59 (p, J = 7.0 Hz,
4H), 1.38-1.48 (m, 4H).
Methyl 5-(7-hydroxyheptyl)furan-2-carboxylate (149): To a Parr flask was added 148 (1.99 g,
8.42 mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was
carried out at 55 psi of H2 for 18 h. The reaction mixture was filtered through Celite, washed with
MeOH (100 mL) and concentrated under reduced pressure to give 1.5 g (74%) of 149. Light brown
liquid; TLC Rf 0.53 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.11-7.13 (d, J =
3.4 Hz, 1H), 6.13-6.15 (d, J = 3.3 Hz, 1H), 3.90 (s, 3H), 3.64-3.68 (t, J = 6.6 Hz, 2H), 2.69-2.73
(t, J = 7.6 Hz, 2H), 1.67-1.74 (dd, J = 4.4, 10.2 Hz, 2H), 1.55-1.60 (q, J = 6.5 Hz, 2H), 1.35-1.39
(d, J = 4.2 Hz, 6H), 1.31 (s, 1H).
Methyl 5-(7-oxoheptyl)furan-2-carboxylate (150): To a stirred solution of Dess-Martin
periodinane (3.18 g, 7.49 mmol) in CH2Cl2 (8 mL), methyl 5-(7-hydroxyheptyl)furan-2carboxylate, 149 (1.5 g, 6.24 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was
continued for 3 h and the mixture was allowed to warm to room temperature. When the reaction
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was complete, excess oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous
stirring, the mixture was diluted with ethyl acetate (10 mL), the organic layer was separated, and
the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extracts were
washed with brine, dried with MgS04, and concentrated to afford 150 (1.05 g, yield 71%). Yellow
liquid; TLC Rf 0.67 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d): δ 9.78-9.79 (t, J =
1.7 Hz, 1H), 7.11-7.13 (d, J = 3.4 Hz, 1H), 6.13-6.15 (m, 1H), 3.90 (s, 3H), 2.69-2.73 (t, J = 7.6
Hz, 2H), 2.43-2.47 (td, J = 1.8, 7.3 Hz, 2H), 1.61-1.75 (m, 4H), 1.35-1.43 (m, 4H).
Methyl 5-(6-bromo-7-oxoheptyl)furan-2-carboxylate (151). To 1,4-dioxane (679.42 mg, 7.71
mmol) dissolved in CH2Cl2 (3ml), Br2 (704.20 mg, 225.7 mmol) was added dropwise and the
mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added dropwise
to an ice-cool solution of 150 (1.05 g, 4.41 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The mixture
was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being stirred for
1h, the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new non polar
spot was identified. The compound, 151, was unstable, so, it was immediately used for the next
step.
Methyl

5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2-

carboxylate (152). To a solution of 2,6-diamino-4-oxopyrimidine (1.1 g, 4.86 mmol) and sodium
acetate (724.18 mg, 8.83 mmol) in water (10 mL) and methanol (10 mL) was added α-bromo
aldehyde 151 (4.41 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed the
disappearance of starting materials and the formation of one major spot at Rf = 0.65
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by
celite (4 g). Evaporation of the solvent afforded a plug, which was eluted by combiflash. Fractions
showing Rf = 0.65 were pooled and evaporated to afford 152 (350 mg, yield 23% over two steps).
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Orange brown powder. MP > 148 °C (decomposed); TLC Rf 0.65 (CHCl3/MeOH, 5:1); 1H NMR
(DMSO-d6): δ 10.61 (s, 1H), 10.10 (s, 1H), 7.21-7.22 (d, J = 3.5 Hz, 1H), 6.34-6.35 (d, J = 3.5
Hz, 1H), 6.32-6.33 (d, J = 2.0 Hz, 1H), 5.97 (s, 2H), 3.78 (s, 3H), 2.66-2.70 (t, J = 7.6 Hz, 2H),
2.54-2.56 (d, J = 8.5 Hz, 2H), 1.57-1.66 (h, J = 7.5 Hz, 4H), 1.33-1.36 (q, J = 7.8 Hz, 2H). Anal.
calculated for (C17H20N4O4 · 0.85 CH3OH): C, 57.69; H, 6.35; N, 15.08; Found: C, 58.17; H, 6.25;
N, 14.62.
5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2carboxylic acid (153). To 152 (162 mg, 0.47 mmol) was added 1 N NaOH (3 mL). The resulting
mixture was stirred at room temperature for 2 hrs. TLC indicated the disappearance of starting
material and the formation of one major spot at Rf = 0.33 (CHCl3/MeOH, 5:1). To this was added
distilled water (3 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using
1 N HCl. The resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate
was filtered, washed with cold water, and dried in a desiccator under reduced pressure using P2O5
to afford 153 (143 mg, yield 92%). Pale yellowish white powder; TLC Rf 0.33 (CHCl3/MeOH,
5:1); 1H NMR (DMSO-d6): δ 12.84 (s, 1H), 10.60-10.63 (d, J = 2.2 Hz, 1H), 10.12 (s, 1H), 7.107.12 (d, J = 3.3 Hz, 1H), 6.33-6.34 (d, J = 2.0 Hz, 1H), 6.30-6.31 (d, J = 3.4 Hz, 1H), 5.99 (s, 2H),
2.64-2.68 (t, J = 7.5 Hz, 2H), 2.54-2.56 (d, J = 7.5 Hz, 2H), 1.58-1.66 (qd, J = 3.7, 8.0 Hz, 4H),
1.29-1.37 (h, J = 6.4, 7.3 Hz, 2H). Anal. calculated for (C16H18N4O4 · 0.62 CH3OH): C, 56.98; H,
5.89; N, 15.98; Found: C, 57.07; H, 5.76; N, 15.83.
(S)-diethyl(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan2-carbonyl)-L-glutamate (154): In 20 mL DMF, 153 (101 mg, 0.305 mmol) was added. Then 2chloro-4,6-dimethoxy-1,3,5-triazine (64.42 mg, 0.366 mmol), N-methylmorpholine (77.31 mg,
0.764 mmol) and L-glutamate diethyl ester hydrochloride (94.45 mg, 0.464 mmol) were added in
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the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a
major new spot at Rf = 0.66 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired
single spot at Rf = 0.66 were pooled and evaporated to dryness to afford 154 (157 mg, yield 99%).
Dark green powder; MP 110 °C; TLC Rf 0.66 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSOd6): δ 10.61 (s, 1H), 10.10 (s, 1H), 8.47-8.49 (d, J = 7.9 Hz, 1H), 7.06-7.07 (d, J = 3.5 Hz, 1H),
6.34 (s, 1H), 6.27-6.29 (d, J = 3.4 Hz, 1H), 5.97 (s, 2H), 4.36-4.42 (q, J = 7.8 Hz, 1H), 4.08-4.13
(q, J = 7.0 Hz, 2H), 4.01-4.07 (q, J = 7.0 Hz, 2H), 2.64-2.68 (t, J = 7.6 Hz, 2H), 2.53-2.56 (s, 2H),
2.38-2.42 (t, J = 7.2 Hz, 2H), 1.95-2.12 (m, 2H), 1.59-1.67 (q, J = 8.3 Hz, 4H), 1.32-1.36 (m, 2H),
1.14-1.20 (dt, J = 7.0, 10.0 Hz, 6H). Anal. calculated for (C25H33N5O7 · 0.9 H2O): C, 56.47; H,
6.6; N, 13.17; Found: C, 55.27; H, 6.71; N, 14.43.
(S)-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)furan-2carbonyl)-L-glutamic acid (9). To 154 (75 mg, 0.145 mmol) was added 1 N NaOH (2 mL). The
resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the disappearance of
starting material and the formation of one very polar major spot. To this was added distilled water
(2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered,
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 9
(45 mg, yield 67%). Pale greenish white powder; TLC Rf 0.3 (CHCl3/MeOH, 5:1 in acidic
condition); 1H NMR (DMSO-d6): δ 12.53 (s, 2H), 10.68 (s, 1H), 10.25 (s, 1H), 8.34-8.36 (d, J =
8.0 Hz, 1H), 7.06-7.07 (d, J = 3.4 Hz, 1H), 6.36-6.37 (d, J = 2.0 Hz, 1H), 6.26-6.27 (d, J = 3.3 Hz,
1H), 6.14 (s, 2H), 4.32-4.38 (ddd, J = 4.8, 7.9, 9.9 Hz, 1H), 2.64-2.68 (d, J = 7.6 Hz, 2H), 2.5376

2.57 (t, J = 7.7 Hz, 2H), 2.30-2.34 (t, J = 7.4 Hz, 2H), 1.89-2.12 (m, 2H), 1.59-1.69 (h, J = 8.1 Hz,
4H), 1.33-1.38 (q, J = 7.7 Hz, 2H). Anal. calculated for (C21H25N5O7 · 0.21 CHCl3): C, 52.57; H,
5.24; N, 14.45; Found: C, 52.58; H, 5.60; N, 14.32.
Methyl 2-fluoro-4-(4-hydroxybut-1-yn-1-yl)benzoate (157): To a 20-mL vial for microwave
reaction, was added a mixture of palladium chloride (182.15 mg, 1.03 mmol), triphenylphosphine
(269.44 mg, 1.03 mmol), triethylamine (6.5 g, 64.20 mmol methyl 4-bromo-2-fluorobenzoate, 155
(1.5 g, 6.42 mmol) and anhydrous acetonitrile (8 mL). To the stirred mixture, were added copper(I)
iodide (195.64 mg, 1.03 mmol), and but-3-yn-1-ol, 156 (450 mg, 6.42 mmol), and the vial was
sealed and put into the microwave reactor at 100 °C for 1 h. TLC showed a new spot with Rf =
0.62 (hexane/EtOAc 1:1). This reaction was repeated two more time with similar outcome. Three
reaction mixtures were mixed and solvent (acetonitrile) was evaporated. Then methanol and celite
(10 g) was added and the solvent was evaporated under reduced pressure. The resulting plug was
subjected to flash chromatography using combiflash machine in EtOAc/hexane system. The
desired fraction (TLC) was collected and the solvent was evaporated under reduced pressure to
afford 157 (2.7 g, yield 63%). Brown semisolid; TLC Rf 0.62 (hexane/EtOAc 1:1); 1H NMR (400
MHz, Chloroform-d): δ 7.87-7.91 (t, J = 7.8 Hz, 1H), 7.17-7.26 (m, 2H), 3.95 (s, 3H), 3.84-3.88
(q, J = 5.8 Hz, 2H), 2.72-2.75 (t, J = 6.3 Hz, 2H), 1.85-1.88 (t, J = 6.0 Hz, 1H).
Methyl 2-fluoro-4-(4-hydroxybutyl)benzoate (158): To a Parr flask was added 157 (2 g, 9
mmol), 10% palladium on activated carbon (2 g), and MeOH (100 mL). Hydrogenation was carried
out at 55 psi of H2 for 9 h. The reaction mixture was filtered through Celite, washed with MeOH
(100 mL) and concentrated under reduced pressure to give 1.93 g (95%) of 158. Colorless liquid;
TLC Rf 0.56 (hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d):  7.85-7.88 (t, J = 7.8 Hz,
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1H), 6.96-7.05 (m, 2H), 3.93 (s, 3H), 3.67-3.70 (t, J = 6.3 Hz, 2H), 2.68-2.72 (t, J = 7.6 Hz, 2H),
1.58-1.78 (m, 4H), 1.43 (s, 1H).
Methyl 2-fluoro-4-(4-oxobutyl)benzoate (159): To a stirred solution of Dess-Martin periodinane
(4.34 g, 10.24 mmol) in CH2Cl2 (8 mL), methyl 2-fluoro-4-(4-hydroxybutyl)benzoate, 158 (1.93
g, 8.53 mmol) in anhydrous CH2Cl2 (8 mL) was added at 0 °C. Stirring was continued for 3 h and
the mixture was allowed to warm to room temperature. When the reaction was complete, excess
oxidant was destroyed by the addition of 1N NaOH. After 30 min of vigorous stirring, the mixture
was diluted with ethyl acetate (10 mL), the organic layer was separated, and the aqueous layer was
extracted with ethyl acetate (2 x 10 mL). The combined extracts were washed with brine, dried
with MgS04, and concentrated to afford 159 (853 mg, yield 45%). Colorless liquid; TLC Rf 0.68
(hexane/EtOAc 1:1); 1H NMR (400 MHz, Chloroform-d): δ 9.80-9.81 (t, J = 1.4 Hz, 1H), 7.877.91 (t, J = 7.8 Hz, 1H), 6.97-7.05 (m, 2H), 3.94 (s, 3H), 2.69-2.73 (m, 2H), 2.49-2.53 (td, J = 1.4,
7.3 Hz, 2H), 1.95-2.03 (p, J = 7.3 Hz, 2H).
Methyl 4-(3-bromo-4-oxobutyl)-2-fluorobenzoate (160). To 1,4-dioxane (618.17 mg, 600.16
mmol) dissolved in CH2Cl2 (3 ml), Br2 (640.71 mg, 205.36 mmol) was added dropwise and the
mixture was stirred for 10 min, and diluted with CH2Cl2 (3 ml). This solution was added dropwise
to an ice-cool solution of 159 (899 mg, 4.01 mmol) in CH2Cl2 (5 ml) over 3 h under N2. The
mixture was stirred for 0.5 h, then a solution of Na2CO3 in water (10 ml) was added. After being
stirred for 1h, the reaction mixture was extracted with CHCl3 (2 x 10 ml). TLC was run and a new
non polar spot was identified. The compound, 160, was unstable, so, it was immediately used for
the next step.
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Methyl

4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-

fluorobenzoate (161). To a solution of 2,6-diamino-4-oxopyrimidine (558.35 mg, 4.43 mmol) and
sodium acetate (660.32 mg, 8.05 mmol) in water (10 mL) and methanol (10 mL) was added αbromo aldehyde 160 (4.02 mmol). The reaction mixture was stirred at 45 °C for 12 h. TLC showed
the disappearance of starting materials and the formation of one major spot at Rf = 0.54
(CHCl3/MeOH, 5:1). After evaporation of the solvent, CH3OH (10 mL) was added followed by
celite (4 g). Evaporation of the solvent afforded a plug, which was eluted by combiflash
(CHCl3/MeOH system). Fractions showing Rf = 0.54 were pooled and evaporated to afford 161
(608 mg, yield 46% over two steps). Pink powder; TLC Rf 0.54 (CHCl3/MeOH, 5:1); 1H NMR
(DMSO-d6): 10.65 (s, 1H), 10.19 (s, 1H), 7.77-7.81 (t, J = 8.0 Hz, 1H), 7.14-7.18 (m, 2H), 6.316.33 (d, J = 2.1 Hz, 1H), 6.03 (s, 2H), 3.83 (s, 4H), 2.99-3.02 (dd, J = 6.3, 9.1 Hz, 2H), 2.84-2.88
(dd, J = 6.2, 9.2 Hz, 2H). Anal. calculated for (C16H15FN4O3 · 0.46 H2O): C, 56.74; H, 4.74; N,
16.54; F, 5.60; Found: C, 56.75; H, 4.55; N, 16.48; F, 5.48.
4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-fluorobenzoic
acid (162). To 161 (458 mg, 1.39 mmol) was added 1 N NaOH (3 mL). The resulting mixture was
stirred at room temperature for 2 hrs. TLC indicated the disappearance of starting material and the
formation of one major spot at Rf = 0.45 (CHCl3/MeOH, 5:1). To this was added distilled water
(3 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The
resulting suspension was thawed to 4 °C overnight in a refrigerator. The precipitate was filtered,
washed with cold water, and dried in a desiccator under reduced pressure using P2O5 to afford 162
(420 mg, yield 96%). Light pink powder; MP > 274 °C (decomposed); TLC Rf 0.45
(CHCl3/MeOH, 5:1); 1H NMR (DMSO-d6): δ 10.65 (s, 1H), 10.19 (s, 1H), 7.74-7.78 (t, J = 7.9
Hz, 1H), 7.11-7.13 (d, J = 9.8 Hz, 2H), 6.31-6.33 (d, J = 2.1 Hz, 1H), 6.04 (s, 2H), 2.97-3.01 (t, J
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= 7.6 Hz, 2H), 2.84-2.88 (t, J = 7.7 Hz, 2H). Anal. calculated for (C15H13FN4O3 · 1 CH3OH): C,
53.87; H, 4.52; N, 16.75; F, 5.68; Found: C, 53.97; H, 4.42; N, 16.47; F, 5.42.
(S)-diethyl

(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2-

fluorobenzoyl)-L-glutamate (163): In 20 mL DMF, 162 (300 mg, 0.948 mmol) was added. Then
2-chloro-4,6-dimethoxy-1,3,5-triazine (199.83 mg, 1.14 mmol), N-methylmorpholine (239.85 mg,
2.37 mmol) and L-glutamate diethyl ester hydrochloride (293.01 mg, 1.44 mmol) were added in
the stirred solution. This was stirred at room temperature for 12 hrs. TLC showed formation of a
major new spot at Rf = 0.60 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness
under reduced pressure. The residue was dissolved in MeOH, celite added and solvent evaporated
to make a plug. From column run in combiflash (CHCl3/MeOH), factions that showed the desired
single spot at Rf = 0.60 were pooled and evaporated to dryness to afford 163 (280 mg, yield 59%).
Grey powder; MP > 228 °C (decomposed); TLC Rf 0.60 (CHCl3/MeOH, 5:1); 1H NMR (400
MHz, DMSO-d6): δ 10.64 (d, J = 2.2 Hz, 1H), 10.17 (s, 1H), 8.57-8.59 (dd, J = 2.0, 7.5 Hz, 1H),
7.47-7.51 (t, J = 7.7 Hz, 1H), 7.10-7.13 (m, 2H), 6.32-6.34 (d, J = 2.0 Hz, 1H), 6.06 (s, 2H), 4.384.45 (ddd, J = 5.0, 7.4, 9.5 Hz, 1H), 4.08-4.15 (qd, J = 2.1, 7.2 Hz, 2H), 4.03-4.08 (q, J = 7.1 Hz,
2H), 2.96-3.02 (dd, J = 6.1, 9.1 Hz, 2H), 2.83-2.88 (dd, J = 6.3, 9.1 Hz, 2H), 2.41-2.46 (td, J = 2.5,
6.9, 7.4 Hz, 2H), 1.90-2.13 (m, J = 7.5, 13.1 Hz, 2H), 1.14-1.23 (dt, J = 7.1, 11.0 Hz, 6H). Anal.
calculated for (C24H28FN5O6 · 1.4 H2O): C, 54.73; H, 5.89; N, 13.3; F, 3.61; found: C, 50.08; H,
5.16; N, 18.02; F, 2.67.
(S)-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)-2fluorobenzoyl)-L-glutamic acid (10). To 163 (122 mg, 0.369 mmol) was added 1 N NaOH (2
mL). The resulting mixture was stirred at room temperature for 3 hrs. TLC indicated the
disappearance of starting material and the formation of one very polar major spot. To this was
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added distilled water (2 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to
4 using 1 N HCl. The resulting suspension was thawed to 4 °C overnight in a refrigerator. The
precipitate was filtered, washed with cold water, and dried in a desiccator under reduced pressure
using P2O5 to afford 10 (65 mg, yield 56%). Light green powder; TLC Rf 0.22 (CHCl3/MeOH,
5:1 in acidic condition); 1H NMR (DMSO-d6): δ 10.64-10.65 (d, J = 2.3 Hz, 1H), 10.18 (s, 1H),
8.42-8.44 (m, 1H), 7.50-7.54 (t, J = 7.7 Hz, 1H), 7.10-7.12 (d, J = 9.6 Hz, 2H), 6.32-6.34 (d, J =
2.0 Hz, 1H), 6.04 (s, 2H), 4.39 (t, J = 11.1 Hz, 1H), 2.97-3.01 (dd, J = 6.0, 9.2 Hz, 2H), 2.84-2.88
(m, 2H), 2.33-2.35 (d, J = 8.2 Hz, 2H), 1.91-2.09 (m, 2H). Anal. calculated for (C20H20FN5O6 ·
1.23 CH3OH): C, 52.59; H, 5.18; N, 14.44; F, 3.91; Found: C, 52.24; H, 4.95; N, 14.69; F, 3.85.
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APPENDIX
The biological evaluations of the analogs listed in the following tables were performed by
Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos Cancer
Institute and the Cancer Biology Program and Department of Pharmacology, Wayne State
University School of Medicine) against RFC-expressing PC43-10 cells, FRα-expressing RT16
cells, FRβ-expressing D4 cells and hPCFT-expressing R2/hPCFT4 cells. The activities of PMX,
MTX, RTX and LMTX were already reported in the literature.
Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of Western
Ontario) and were cultured in R-minimal essential medium (MEM) supplemented with 10%
bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution and L-glutamine
at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. RT16 cells are R2 cells
transfected with human FRα, and D4 cells are R2 cells transfected with human FRβ. R2/hPCFT4
cells were prepared by transfection of R2 cells with an hPCFT cDNA, epitope tagged at the Cterminus with Myc-His6 (hPCFTMyc-His6) and cloned in pCDNA3.1. All the R2 transfected cells
(PC43- 10, RT16, D4, R2/hPCFT4) were routinely cultured in R-MEM plus 1.5 mg/mL G418.
Prior to the cytotoxicity assays, RT16 and D4 cells were cultured in complete folate-free
RPMI1640 (without added folate) for 3 days. KB human cervical cancer cells were purchased from
the American Type Culture Collection (Manassas, VA). Cells were routinely cultured in folatefree RPMI1640 medium, supplemented with 10% fetal bovine serum, penicillin-streptomycin
solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth inhibition assays, cells (CHO
or KB) were plated in 96 well dishes (∼2500-5000 cells/well, total volume of 200 µL medium)
with a broad range of antifolate concentrations. The medium was RPMI1640 (contains 2.3 µM

95

folic acid) with 10% dialyzed serum and antibiotics for experiments with R2 and PC43-10 cells.
For RT16, D4 and KB cells, the cells were cultured in folate-free RPMI media with 10% dialyzed
fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM LCV. The requirement
for FR mediated drug uptake in these assays was established in a parallel incubation including 200
nM folic acid. For R2/hPCFT4 cells, the medium was folate-free RPMI1640 (pH 7.2) containing
25 nM LCV, supplemented with 10% dialyzed fetal bovine serum (Invitrogen) and antibiotics.
Cells were routinely incubated for up to 96 h, and metabolically active cells (a measure of cell
viability) were assayed with Cell Titer-blue cell viability assay (Promega, Madison, WI), with
fluorescence measured (590 nm emission, 560 nm excitation) using a fluorescence plate reader.
Raw data were exported from Softmax Pro software to an Excel spreadsheet for analysis and
determinations of IC50s, corresponding to the drug concentrations that result in 50% loss of cell
growth. For assays of colony formation in the presence of the antifolate drugs, KB cells were
harvested and diluted, and 200 cells were plated into 60 mm dishes in folate-free RPMI1640
medium supplemented with 2 nM LCV, 10% dialyzed fetal bovine serum, penicillin-streptomycin,
and 2 mM L-glutamine in the presence of antifolate drugs. The dishes were incubated at 37 °C
with 5% CO2 for 10-14 days. At the end of the incubations, the dishes were rinsed with Dulbecco’s
phosphate-buffered saline (DPBS), 5%trichloroacetic acid, and borate buffer (10 mM, pH 8.8),
followed by 30 min incubation in 1% methylene blue in the borate buffer. The dishes were rinsed
with the borate buffer, and colonies were counted for calculating percent colony-forming
efficiency normalized to control.
Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells grown
as monolayers were used to seed spinner flasks. For experiments to determine the inhibitions of
transport by antifolate substrates, cells were collected and washed with DPBS and resuspended in
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2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-10 cells and in HBS adjusted
to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-buffered saline (20 mM MES, 140
mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) adjusted to pH 6.5, 6.0, or 5.5 for
R2/hPCFT4 cells. In either case, uptakes of [3H]MTX (0.5 µM) were measured over 2 min at 37
°C in the presence and absence of unlabeled antifolates (10 µM). Uptakes of [3H]MTX were
quenched with ice-cold DPBS. Cells were washed with icecold DPBS (3×) and solubilized with
0.5 N NaOH. Levels of intracellular radioactivity were expressed as pmol/mg protein, calculated
from direct measurements of radioactivity and protein contents of cell homogenates. Protein
concentrations were measured with Folin phenol reagent. Percent MTX transport inhibition was
calculated by comparing level of [3H]MTX uptake in the presence and absence of the inhibitors.
Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and Dixon plots,
respectively.
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